Stocks · 1,125 research notes · 18 current themes
AI stock research, one note per stock.
A full research note on every stock we cover: what Claude thinks and why, the case for and against, the dates that matter and the kill line that would prove it wrong. Written by Claude from each company's filings, releases, news and analyst moves, and dated, so you always know how fresh it is.
1,125 shown
No stocks match your filters.
Filter by conviction, archetype or theme
Conviction, each note's three-month call against the S&P 500: High and Medium expect the shares to lead it, Low expects them to lag it.
In the portfolio
12The portfolio holds this stock right now. What this means
APPNAppianMedium Appian's third-quarter 2026 revenue rose 25% to $234.6 million and full-year guidance went up again, giving the shares a modest edge over the S&P 500; the fourth-quarter report, expected around 18 February 2027, shows whether cloud…CHYMChime FinancialMedium Chime Financial's revenue growth sped up to 32% and its 2026 outlook rose a third time, giving the shares a modest edge over the S&P 500 over three months; the fourth-quarter 2026 report, against a $757–767 million forecast, settles it.ETONEton PharmaceuticalsMedium Eton Pharmaceuticals is modestly more likely than not to beat the S&P 500 over three months, after third-quarter revenue of $57.9 million, up 158%, lifted its 2026 guide above $175 million. The fourth-quarter report, expected around…IMAXMedium IMAX Corporation's shares are modestly more likely than not to beat the S&P 500 over three months on a record third quarter and a raised margin target; Dune: Part Three's 18 December 2026 opening and 2027 box-office guidance due early 2027…KNSAKiniksa Pharmaceuticals InternationalMedium Kiniksa Pharmaceuticals is modestly more likely than not to beat the S&P 500 over three months on its third 2026 ARCALYST guidance raise, to $1.045–1.050 billion. Fourth-quarter sales and the first 2027 range, due in the early-2027 results…LLYEli LillyMedium Eli Lilly's shares are more likely than not to beat the S&P 500 over three months, as tirzepatide volume still outruns price cuts and Foundayo won China approval on 12 November 2026. The fourth-quarter report and 2027 outlook, expected…MSFTMicrosoftMedium Microsoft's shares are modestly more likely to lead the S&P 500 over three months because Azure grew 48% in the September quarter and is guided to 49–50% for December. The fiscal second-quarter report, expected in late January 2027, shows…PLMRPalomar HoldingsMedium Palomar Holdings is more likely than not to beat the S&P 500 over three months because estimates keep rising after its fourth 2026 guidance raise, to $280–285 million of adjusted net income. The fourth-quarter report, expected around…QNSTQuinStreetMedium QuinStreet's shares are more likely than not to beat the S&P 500 over three months after it beat guidance and raised its fiscal 2027 outlook on 4 November 2026; the early-February 2027 report shows whether insurance-carrier ad spending…UUnity SoftwareMedium Unity Software's advertising turnaround and reported takeover interest make the shares modestly more likely than not to beat the S&P 500 over three months; the fourth-quarter 2026 report, expected around 11 February 2027, settles whether…XERSXeris Biopharma HoldingsMedium Xeris Biopharma's shares are modestly more likely than not to beat the S&P 500 over three months because Recorlev sales rose 93% to $71.5 million in the third quarter and 2026 revenue guidance rose to $395–405 million. Preliminary…ZETAZeta Global HoldingsMedium Zeta Global's shares hold a modest edge over the S&P 500 after the company beat its third-quarter guide and raised 2026 revenue guidance to $1.853 billion–$1.857 billion on 9 November 2026; the fourth-quarter report, expected in February…
Watching
347The research is following this stock now; the portfolio does not hold it. What this means
AZTAAzentaHigh Azenta is more likely to beat the S&P 500 over three months because its fiscal 2027 plan, issued 10 November 2026, adds 3% to 5% organic growth and a wider margin. The fiscal first-quarter report, expected around early February 2027, shows…AAMIAcadian Asset ManagementMedium Acadian Asset Management's eleven straight quarters of client inflows, record fees and resumed buybacks give its shares a modest edge over the S&P 500. The fourth-quarter report, expected in late January 2027, shows whether flows stay…AAPLAppleMedium Apple's above-consensus 7–10% December-quarter revenue guide gives the shares a modest edge over the S&P 500. The fiscal first-quarter report due around late January 2027 settles it by showing whether iPhone Duo sales outrun memory costs…ABBVAbbVieMedium AbbVie's Skyrizi and Rinvoq, each up more than 22% in the 30 October 2026 third-quarter report, keep lifting guidance and analyst targets, so the shares modestly favour beating the S&P 500. The fourth-quarter report expected around 29…ADMAADMA BiologicsMedium ADMA Biologics' ASCENIV immune globulin grew 31% in Q3 2026 and profit guidance was raised, though revenue guidance stayed at "at least $530 million"; fourth-quarter ASCENIV demand and pricing settle whether the post-report gain holds.ADPTAdaptive BiotechnologiesMedium Adaptive Biotechnologies is more likely than not to beat the S&P 500 over three months because clonoSEQ tests rose 46% in the third quarter of 2026 and MRD revenue guidance rose to $276–286 million. Medicare's final 2027 lab rates,…AGLagilon healthMedium agilon health roughly doubled its 2026 adjusted EBITDA guidance to $145–$155 million after a second profitable quarter, giving the shares a modest edge over the S&P 500; the 17 November 2026 investor event and the Q4 report show whether…ALGTAllegiant TravelMedium Allegiant Travel Company is modestly more likely to beat the S&P 500 over three months as fares outrun fuel; its 7 December 2026 investor day shows whether 2027 targets back the above-$6.00 2026 earnings guide.AMDAdvanced Micro DevicesMedium Advanced Micro Devices is modestly more likely than not to beat the S&P 500: Helios AI racks and doubling server-processor sales back a $17 billion fourth-quarter guide and more than 80% revenue growth forecast for 2027. AMD's…AMGNAmgenMedium Amgen is modestly more likely than not to beat the S&P 500 over three months because Repatha, Evenity and newer drugs are outgrowing biosimilar losses. The fourth-quarter report and 2027 outlook, expected in early February 2027, settle it.AMZNAmazon.comMedium Amazon.com's shares are modestly more likely to beat the S&P 500 over three months as AWS revenue grew 39% last quarter on a $578 billion backlog; Anthropic's IPO pricing, expected around 18 November 2026, and the fourth-quarter report…ANETArista NetworksMedium Arista Networks' guide for about $18.5 billion of 2027 revenue, near 40% growth, gives its shares a modest edge over the S&P 500 after a rebound to $206.63 on 12 November 2026. Nvidia's 17 November 2026 results set the tone for AI…APOGApogee EnterprisesMedium Apogee Enterprises' shares are modestly more likely to beat the S&P 500 because pricing and cost gains lifted fiscal 2027 adjusted EPS guidance to $3.00–$3.40 on 6 October 2026. The report expected around 6 January 2027 shows whether those…APPAppLovinMedium AppLovin's third-quarter 2026 revenue rose 55% to $2.185 billion and put growth back on track. The fourth-quarter report, expected around February 2027, shows whether its partly rolled-out ad models hold growth above the guided 43–44%.ARHSArhausMedium Arhaus's furniture orders are running far ahead of deliveries, giving the shares a modest edge over the S&P 500: Q3 2026 comparable written sales rose 13.9% and client deposits reached $325.0 million. The Q4 2026 report, expected in late…ARXSArxisMedium Arxis, a defense, space and industrial component roll-up, is modestly likely to beat the S&P 500 after 29% organic growth and a raised outlook on 28 October 2026. Its fourth-quarter report, due about late February 2027, tests whether…AVEXAEVEXMedium AEVEX's core drone and maritime business is outgrowing its fading Ukraine work, making the shares modestly likely to beat the S&P 500 over three months. First orders under its nearly $400 million drone contract and the 2027 outlook at the…AVGOBroadcomMedium Broadcom's shares look modestly more likely to beat the S&P 500 over three months as Nvidia's CEO exit and Anthropic's near-priced IPO draw buyers to its custom AI chips. The 9 December 2026 fourth-quarter report, against a $21.7 billion…AVTRAvantorMedium Avantor's lab-supply volumes are growing again, with Q3 2026 organic growth of 5.2% and a raised FY2026 outlook, but distribution margins fell. The 8 December 2026 Investor Day shows whether margin targets support further gains in the…AXGNAxogenMedium Axogen's nerve-repair revenue grew 26.2% last quarter and a $754 million prostate market sits outside guidance, giving the shares a modest edge over the S&P 500; the Q4 2026 report settles whether revenue excluding BioCircuit reaches the…BHCBausch Health CompaniesMedium Bausch Health's recovery is backed by a third-quarter beat and a second guidance raise on 28 October 2026, but $20.2 billion of debt principal keeps the shares highly sensitive; the fourth-quarter report, expected in early 2027, tests the…BTSGBrightSpring Health ServicesMedium BrightSpring Health Services is growing profit faster than revenue, with third-quarter 2026 adjusted EBITDA up 42% on specialty pharmacy margins and acquired home-health branches. Its first 2027 guidance, expected around late February…BWLPBW LPGMedium BW LPG Limited's shares are more likely to beat the S&P 500 because about 92% of third-quarter ship days were booked near $88,000 a day against $74,000 realised in the second quarter; the 24 November 2026 report shows whether earnings and…CCitigroupMedium Citigroup is modestly more likely to beat the S&P 500 over three months: its returns beat its 11% target while the shares fell 10.5% on market-wide selling. The mid-January 2027 fourth-quarter report shows whether returns and buybacks hold.CBRSCerebras SystemsMedium Cerebras Systems is modestly more likely to beat the S&P 500 over three months after guiding fourth-quarter core revenue to $310–330 million, above the $271 million consensus, and adding Microsoft as a cloud customer. The fourth-quarter…CDNACareDxMedium CareDx's shares are modestly more likely than not to beat the S&P 500: transplant testing revenue grew 39% in the third quarter excluding catch-up collections and 2026 guidance rose to $520–530 million. CMS's final 2027 Medicare rates, due…CDRECadre HoldingsMedium Cadre Holdings' 30% third-quarter sales jump to $202.9 million, 10% organic growth and first $100 million buyback give the shares a modest edge over the S&P 500. The early-March 2027 fourth-quarter report settles whether sales hold near…CEGConstellation EnergyMedium Constellation Energy's third-quarter beat and raised $12.50–$12.80 guidance make its shares modestly more likely than not to beat the S&P 500; whether data-center limits spread into its mid-Atlantic states and the February report settle it.CHAChagee HoldingsMedium Chagee Holdings is modestly more likely to lead the S&P 500 over three months: its shares cleared $14.00 on a $1.95 special dividend. The third-quarter report, expected around 27 November 2026, shows whether China same-store sales, down…CHDNChurchill DownsMedium Churchill Downs' growing Kentucky machine profit, record third quarter and $750 million buyback outweigh its shrinking Virginia machine revenue; monthly state figures and the fourth-quarter report expected around 25 February 2027 decide…CMCOColumbus McKinnonMedium Columbus McKinnon's Kito Crosby merger is beating profit forecasts and its chief executive bought shares after the 3 November 2026 guidance raise; the fiscal third-quarter report, expected in early February 2027, must show leverage falling…COAGHemab Therapeutics HoldingsMedium Hemab Therapeutics is modestly more likely than not to beat the S&P 500 over three months: its pivotal sutacimig trial has started and cash is guided into 2029. Updated Factor VII deficiency data at the ASH meeting on 14 December 2026 test…COSTCostco WholesaleMedium Costco Wholesale's underlying sales growth held at 7.3% in October and a $30 special dividend followed on 10 November 2026, giving the shares a modest edge over the S&P 500. The November sales report (~2 December 2026) and first-quarter…CPRICapri HoldingsMedium Capri Holdings' Michael Kors turnaround gives the shares a modest edge over the S&P 500 after the 30 October 2026 beat-and-raise, despite a CEO handover on 4 January 2027. The fiscal third-quarter report, expected in early February 2027,…CRLCharles River Laboratories InternationalMedium Charles River Laboratories' preclinical recovery passed its 4 November 2026 test with 4.7% organic growth, a 1.09 book-to-bill and raised guidance, and the $470 million Frontage deal adds clinical testing; the fourth-quarter report,…CROXCrocsMedium Crocs, Inc. is more likely to lead the S&P 500 over three months: a third-quarter beat and a third guidance raise lifted full-year adjusted EPS to $14.45–$14.65, and the fourth-quarter report due around mid-February 2027 settles it.CRSRCorsair GamingMedium Corsair Gaming's recovery case holds after it beat third-quarter guidance and raised its 2026 outlook on 5 November 2026; the fourth-quarter report shows whether profit holds as memory gross margin falls to 18%–20%.CRWVCoreWeaveMedium CoreWeave's third-quarter beat and 26% higher profit guide on 10 November 2026 give its shares a modestly better-than-even case against the S&P 500; the debt-funding plan, Microsoft's supplier review and Nvidia's leadership change decide…CSTLCastle BiosciencesMedium Castle Biosciences raised 2026 revenue guidance to $385–395 million and held its 50–52% TissueCypher volume growth plan; the fourth-quarter report, expected around 26 February 2027, shows whether that test offsets weaker melanoma volume.CVNACarvanaMedium Carvana is taking share in a flat used-car market, with third-quarter retail units up 39% and more units guided for the fourth quarter. The February 2027 report shows whether volume growth outruns falling profit per car.CVSCVS HealthMedium CVS Health is modestly more likely to beat the S&P 500 over three months: Aetna's costs improved and 2026 guidance rose, and the February 2027 report tests the 2027 outlook of at least $8.65 per share.CYRXCryoPortMedium Cryoport's cold-chain business for cell and gene therapies is growing faster and posted a second positive adjusted EBITDA quarter, with 2026 revenue guidance raised to $197–199 million. The fourth-quarter report settles whether that pace…DCTHDelcath SystemsMedium Delcath Systems' shares are more likely than not to beat the S&P 500 after third-quarter revenue of $35.1 million lifted 2026 guidance to $115–117 million on 9 November 2026; the full-year report, expected around March 2027, shows whether…DHRDanaherMedium Danaher's shares have a modest edge over the S&P 500 because mid-teens bioprocessing orders should reach revenue in 2027. Formal 2027 guidance in late January settles whether growth meets or beats the 4%–5% starting point that management…DUOLDuolingoMedium Duolingo's shares have a modest edge over the S&P 500 because daily user growth reaccelerated to 29% while 2026 guidance rose; the February 2027 report decides whether those users lift bookings growth above this year's 12%.DXCMDexComMedium Dexcom's raised 2026 outlook and 25.3% third-quarter operating margin give the shares a modest edge after a diabetes-device sell-off erased the post-report gain. A Medicare coverage decision for non-insulin type 2 diabetes, which…ECOOkeanis Eco TankersMedium Okeanis Eco Tankers is modestly more likely than not to beat the S&P 500, as fourth-quarter bookings of 71% of fleet days at about $420,000 a day exceed its record third quarter. The February 2027 fourth-quarter report shows whether rates…ELEstee Lauder CompaniesMedium Estée Lauder's turnaround now shows in sales as well as margins, with first-quarter organic sales up 6% and the fiscal 2027 outlook raised; the second-quarter report, estimated for about 3 February 2027, shows whether growth holds against…ELFe.l.f. BeautyMedium e.l.f. Beauty's shares are modestly more likely than not to beat the S&P 500 because the company raised its fiscal 2027 organic sales growth outlook to 9%–11% after 51% quarterly sales growth. The fiscal third-quarter report, expected…EMBCEmbectaMedium Embecta Corp. shares are modestly favored to beat the S&P 500 as higher margins and debt repayment outweigh shrinking U.S. pen-needle sales; the fiscal 2026 report and first fiscal 2027 outlook on 24 November 2026 settle it.ENOVEnovisMedium Enovis Corporation's orthopedic turnaround passed its 5 November 2026 test with 4.6% organic growth, raised earnings guidance and a $200 million buyback. The late-February 2027 full-year report shows whether about 5% growth and at least…EPAMEPAM SystemsMedium EPAM Systems is modestly more likely than not to beat the S&P 500 as its $1.8 billion buyback, including a $500 million UBS repurchase signed 9 November 2026, shrinks the share count; the February 2027 outlook shows whether organic growth…ETSYMedium Etsy's marketplace is growing faster than its own guidance, with third-quarter GMS up 8.8% and buyers growing again, giving the shares a modest edge over the S&P 500. Holiday sales against the $3.46–$3.52 billion fourth-quarter guidance…EVCEntravision CommunicationMedium Entravision's ad-technology unit grew 133% in the third quarter, beating its own guide, and the shares have held the gain; the fourth-quarter report in early 2027 settles whether ATS growth stays above 100%.EVEREverQuoteMedium EverQuote's third-quarter revenue of $218.1 million and adjusted EBITDA of $35.5 million beat the top of its guidance, giving the shares a modest edge over the S&P 500; the fourth-quarter report shows whether profit holds within a lower…EVHEvolent HealthMedium Evolent Health's margin repair now has evidence: Q3 medical costs fell to 93.0% of revenue and 2026 adjusted EBITDA guidance rose to $130–135 million. The late-February Q4 report, with its 2027 range, decides whether the $150 million-plus…FFord MotorMedium Ford Motor's raised 2026 profit guidance and roughly flat 2027 profit target give its shares a modestly better-than-even case to beat the S&P 500; the fourth-quarter report, expected in early February 2027, settles whether that target…FIGSMedium FIGS, the healthcare-apparel maker, holds a modest edge over the S&P 500 after beating third-quarter estimates and raising its 2026 outlook on 5 November 2026, although its CEO sold $79.7 million of stock on 9 November 2026. The…FISVFiservMedium Fiserv's revenue decline has levelled off and management is cutting costs and selling or shutting weak units; the fourth-quarter report, expected around February 2027, settles whether Merchant Solutions returns to its guided 6% to 8%…FLYFirefly AerospaceMedium Firefly Aerospace's third-quarter beat, raised revenue floor and record $1.7 billion backlog make its shares modestly likely to beat the S&P 500; the fourth-quarter Alpha Block II debut settles whether launches carry the $440–450 million…FPSForgent Power SolutionsMedium Forgent Power Solutions is modestly more likely than not to beat the S&P 500 over three months, after beating guidance and guiding fiscal second-quarter revenue to $560–590 million on 12 November 2026; the mid-March 2027 report settles…FTDRfrontdoorMedium Frontdoor's shares are modestly more likely to beat the S&P 500 over three months because renewal pricing, HVAC upgrades and a new $1 billion buyback lift per-share earnings far faster than its 1% member growth. The fourth-quarter report…GDYNGrid Dynamics HoldingsMedium Grid Dynamics' AI work is lifting the IT-services firm back toward double-digit growth at margins near 20%, which favors the shares beating the S&P 500. The Q4 2026 report, expected around late February 2027, shows whether 2027 guidance…GENGen DigitalMedium Gen Digital's raised fiscal 2027 outlook and its step back from a large GoDaddy deal give the shares a modest edge over the S&P 500; the Q3 FY27 report in early 2027 tests the $5.465–5.515 billion revenue range.GICGlobal IndustrialMedium Global Industrial Company's sales strategy is delivering high-single-digit daily sales growth and wider operating margins even without tariff refunds. The fourth-quarter report, expected around late February 2027, settles whether that…GKOSGlaukosMedium Glaukos's iDose TR glaucoma implant and Epioxa keratoconus therapy lifted third-quarter 2026 sales 58% to $211.0 million, giving the shares a modest edge on a $1 billion 2027 outlook. Medicare's pending iDose TR coverage decision and…GMABGenmab A/SMedium Genmab's own cancer drugs are becoming a second engine beside its DARZALEX royalty, with three launches targeted for 2027. ASH data on 14 December 2026 and the 16 December 2026 R&D update show whether filings stay on track.GMEGameStopMedium GameStop's shares hold modestly better-than-even odds of beating the S&P 500 on CEO Ryan Cohen's buying, $5.1 billion of cash and a 43.4 million-share eBay stake. The third-quarter report, projected for about 8 December 2026, settles…GPNGlobal PaymentsMedium Global Payments trades on a reported $40 billion CD&R and GTCR buyout, and nine brokers raised targets after in-line third-quarter results on 5 November 2026; a signed deal at a premium, or word that talks have ended, settles the case.GRNTGranite Ridge ResourcesMedium Granite Ridge Resources has returned production to its guided range and targets about 10% output growth in 2027 on roughly flat spending; its fourth-quarter report and first 2027 guidance, expected around early March 2027, show whether the…GTLBGitLabMedium GitLab's case is that Flex, its usage-based pricing for AI coding agents, lifts fiscal Q3 revenue above the $281–$283 million guidance. The fiscal Q3 report, expected about 1 December 2026, settles it.HAEHaemoneticsMedium Haemonetics' plasma revenue grew 17.7% organically before the CSL Plasma conversion added much, so the larger CSL gain lies ahead; the fiscal third-quarter report around 4 February 2027 shows whether it arrives without a further margin cut.HASHasbroMedium Hasbro's Magic: The Gathering profits and its raised 2026 outlook make the shares modestly more likely than not to beat the S&P 500 over three months. Holiday toy sales from 27 November 2026 and the fourth-quarter report expected around 17…HIPOHippo HoldingsMedium Hippo Holdings has modestly better-than-even odds of beating the S&P 500 after it raised 2026 profit guidance on 29 October 2026 on a falling expense ratio. Fourth-quarter underwriting against its 97–98% combined ratio guidance settles the…HNGEHinge HealthMedium Hinge Health's shares can lead the S&P 500 on 52% revenue growth and a raised $879–881 million 2026 guide; the February 2027 report must show fourth-quarter revenue of at least $249 million to keep the case.HNSTHonestMedium The Honest Company is modestly more likely than not to beat the S&P 500 over three months on record margins and a raised 2026 outlook; the fourth-quarter report, expected around March 2027, settles whether organic growth holds the guided…HTFLHeartflowMedium Heartflow's shares are modestly more likely to beat the S&P 500 over three months: third-quarter revenue rose 57% and the 2026 outlook was raised to $262–264 million, though the shares fell 19.13% on 13 November 2026. The fourth-quarter…HUMHumanaMedium Humana's third-quarter cost beat and higher $9.50 adjusted EPS floor, reported 6 November 2026, make its shares modestly more likely than not to beat the S&P 500 as the Star Ratings recovery lifts 2028 margins. The 10 December investor…ICLRICONMedium ICON plc's orders have recovered into fee-earning work, with a third-quarter direct-fee book-to-bill near 1.3, giving the shares a modest edge over the S&P 500 while earnings per share still trail last year. The fourth-quarter report and…INNSummit Hotel PropertiesMedium Summit Hotel Properties looks modestly more likely than not to beat the S&P 500: it raised 2026 guidance again on 3 November 2026 and October RevPAR rose about 5.5%. The late-February 2027 report shows whether fourth-quarter growth held…INTUIntuitMedium Intuit's shares hold a modest edge over the S&P 500 as AI agents, Credit Karma Tax and the Sequence deal target price-driven customer losses; the 19 November 2026 fiscal Q1 report settles it against the $4.294–$4.313 billion revenue guide.IQVIQVIA HoldingsMedium IQVIA's clinical-research bookings are outpacing revenue, with third-quarter 2026 bookings up 15% at a 1.2x book-to-bill and guidance raised. The 1 December 2026 investor day decides whether that becomes faster 2027 revenue growth.IRONDisc MedicineMedium Disc Medicine's shares are modestly favoured to beat the S&P 500 over three months because bitopertin passed its Phase 3 APOLLO trial on 19 October 2026, answering the FDA's February rejection. ASH pipeline data from 12 December 2026 and…KRMNKarman HoldingsMedium Karman Space & Defense's 66% revenue growth and $1.7 billion backlog make its shares, 66% below their January high, more likely than not to beat the S&P 500. The fourth-quarter report and 2027 outlook, expected around March 2027, settle…KVYOKlaviyoMedium Klaviyo's third-quarter revenue beat, raised 2026 guidance and new $300 million buyback make its shares modestly likely to beat the S&P 500. Fourth-quarter revenue against the $421–425 million guide and the first 2027 outlook settle it.LHLabcorp HoldingsMedium Labcorp's 11.5% Central Labs growth and raised 2026 guidance make its shares modestly more likely to beat the S&P 500 over three months. Final 2027 Medicare lab rates, due from CMS in late November 2026, test the case, and the February…LINDLindblad Expeditions HoldingsMedium Lindblad Expeditions' shares are modestly more likely than not to beat the S&P 500 as 91% occupancy, 6% higher pricing and record 2027 bookings lift profit. The fourth-quarter report and 2027 outlook, expected around late February 2027,…LMTLockheed MartinMedium Lockheed Martin's record $292.0 billion backlog and raised 2026 guidance make the shares modestly more likely than not to beat the S&P 500 after their post-midterm rebound. The 11 December 2026 federal funding deadline shows whether…LQDALiquidiaMedium Liquidia Corporation's shares are modestly more likely to beat the S&P 500 because YUTREPIA sales rose 31% to $222.7 million in the third quarter with record October shipments; preliminary fourth-quarter sales, due in early January 2027,…LUNRIntuitive MachinesMedium Intuitive Machines is modestly more likely than not to beat the S&P 500 over three months after record third-quarter revenue of $269.3 million and a $1.9 billion backlog. The 10-Q's count of at-the-market share sales tests the case, and…MAMastercardMedium Mastercard's card network and faster-growing services keep revenue rising at low double digits, giving its shares a modest edge over the S&P 500; the 16 November 2026 settlement hearing and the late-January report with 2027 guidance settle…MANEVeradermicsMedium Veradermics' hair-loss pill VDPHL01 has finished its male trials with clean 12-month safety and cash of $798.4M guided into 2030. The case now turns on when the company sets a new drug application date, with its 19 November 2026 Jefferies…MANHManhattan AssociatesMedium Manhattan Associates' cloud revenue grew 28% and its backlog 25% in the 27 October 2026 report, making the shares modestly more likely than not to beat the S&P 500. The fourth-quarter report and first 2027 guidance, expected around 27…MAXMediaAlphaMedium MediaAlpha's shares are modestly more likely than not to beat the S&P 500 over three months because insurers keep raising ad spending on its marketplace, shown by its 28 October 2026 beat and an 84% rise in home ad spend. The…MBGLMobility GlobalMedium Mobility Global, the CARFAX owner spun off from S&P Global, is more likely to beat the S&P 500 over three months because its third-quarter organic growth sped up to 7.6% and a $350–450 million buyback is due to start before the end of…MCDMcDonald'sMedium McDonald's US sales turned positive in September and improved through October after a value push, giving the shares a modest edge over the S&P 500; the fourth-quarter report in early 2027 shows whether US traffic has recovered.MCKMcKessonMedium McKesson's earnings keep beating its own guidance, which rose to $45.60–$46.40 of fiscal 2027 adjusted EPS on 4 November 2026; the fiscal third-quarter report, expected in early February 2027, shows whether profit growth holds as oncology…MGNIMagniteMedium Magnite's connected-TV growth beat guidance by a wide margin and lifted its 2026 outlook, giving the shares a modest edge over the S&P 500. The fourth-quarter report, estimated for late February 2027, shows whether growth holds once…MIRMirion TechnologiesMedium Mirion Technologies' nuclear power orders doubled and backlog reached $1.25 billion, supporting shares that lead the S&P 500 from a weak 2026. The mid-February 2027 report shows whether orders become revenue at better margins after the…MNSOMINISO Group HoldingMedium MINISO's 25%-30% mainland China sales growth, against a share price that already reflects lower full-year profit, gives the shares a modest edge; the 17 November 2026 third-quarter report shows whether margins stabilise.MRKMerckMedium Merck's newer drugs and under-the-skin Keytruda are carrying its growth after raised 2026 guidance on 29 October 2026; the early-February 2027 outlook shows whether moderate growth absorbs over $2 billion of generic losses.MRVIMaravai LifeSciences HoldingsMedium Maravai LifeSciences' 4 November 2026 third-quarter report beat estimates and raised full-year revenue and profit guidance, so reported numbers now support the rise in the shares. The fourth-quarter report decides whether the growth holds.MSMorgan StanleyMedium Morgan Stanley's shares have modestly better than even odds of beating the S&P 500, carried by its co-lead role on Anthropic's IPO and record wealth flows. The IPO pricing, reported for 18 November 2026, and the fourth-quarter report,…MTDMettler-Toledo InternationalMedium Mettler-Toledo's third-quarter beat and a 2027 earnings guide above estimates support modest outperformance against the S&P 500; the fourth-quarter report, expected in early February 2027, settles whether about 5% sales growth holds.MTWManitowocMedium Manitowoc's crane orders and raised 2026 guidance give the shares a modest edge over the S&P 500; the fourth-quarter report, expected around February 2027, settles whether about $90 million of fourth-quarter free cash flow arrives.MUMicron TechnologyMedium Micron Technology's shares look modestly more likely than not to beat the S&P 500, as its guidance and CoreWeave's 10 November 2026 outlook point to steady AI memory demand. Nvidia's 17 November 2026 results, its first under an interim…MYGNMyriad GeneticsMedium Myriad Genetics shares look modestly more likely to beat the S&P 500 after third-quarter revenue per test rose 1% and the 2026 revenue guide was raised; the cost of the 2 November 2026 network intrusion to testing volumes and patient data…NEONeoGenomicsMedium NeoGenomics' cancer-testing turnaround is lifting profit faster than revenue, but clinical test volume grew only 1.8% in the third quarter. Pending Medicare decisions on RaDaR ST and the fourth-quarter report will show whether volume…NSITInsight EnterprisesMedium Insight Enterprises' shares are modestly more likely than not to beat the S&P 500 because its raised 2026 earnings guidance ($13.55–$13.75 adjusted EPS) still outruns analysts' targets; the 2 December 2026 investor briefing and a mostly…NTSKNetskopeMedium Netskope's 29% revenue growth and raised fiscal 2027 outlook make the shares modestly more likely than not to beat the S&P 500, with RBC and Mizuho lifting targets in November. The 2 December 2026 fiscal Q3 report settles it: revenue must…OABIOmniAbMedium OmniAb is modestly more likely to beat the S&P 500 over three months because its raised 2026 guidance and $8.3 million of nine-month operating cash inflow show partners can fund its antibody-discovery model. The fourth-quarter report,…ODDODDITY TechMedium ODDITY Tech's third-quarter beat and raised 2026 outlook back a recovery built on steady IL MAKIAGE repeat orders and a growing SpoiledChild. The fourth-quarter report, expected in late February 2027, shows whether the advertising-partner…OLLIOllie's Bargain Outlet HoldingsMedium Ollie's Bargain Outlet shares are modestly more likely than not to beat the S&P 500, supported by a $500 million buyback and three analyst target increases since mid-October. The early-December third-quarter report shows whether comparable…ONONOn HoldingMedium On Holding's shares are rated modestly more likely to beat the S&P 500 because the company kept FY2026 sales guidance and plans faster fourth-quarter growth; holiday sales from 27 November 2026 and the Q4 report around March 2027 settle it.ONTOnterrisMedium Onterris's shares trade on a board-led strategic review that has engaged outside buyers and on a third-quarter cash flow recovery; a review outcome and fourth-quarter operating cash flow against the $30.0M–$40.0M guide settle the case.OPRTOportun FinancialMedium Oportun Financial's Q3 2026 beat and raised full-year guidance put its profit recovery on firmer ground as lending grows again; the Q4 report, expected around March 2027, tests whether $49–$54 million of adjusted EBITDA and an 11.05%…ORKAOruka TherapeuticsMedium Oruka Therapeutics is modestly more likely to beat the S&P 500 over three months: its psoriasis antibody ORKA-001 cleared skin completely in 61% of high-dose patients against 0% on placebo, and the December 2026 52-week EVERLAST-A data…PARPAR TechnologyMedium PAR Technology's restaurant software is growing faster than its share price assumed: recurring revenue rose 18.1% and 2026 guidance was raised on 5 November 2026. The late-February 2027 fourth-quarter report shows whether organic growth…PCORProcore TechnologiesMedium Procore Technologies' third-quarter beat and raised 2026 outlook give the shares a modest edge over the S&P 500 even after a 29.1% three-month rise; the fourth-quarter report, expected around February 2027, settles whether growth and the…PGProcter & GambleMedium Procter & Gamble's volume-led growth restart, with organic sales up 4% last quarter, makes it modestly likelier to beat the S&P 500 while Brent near $96 stays under the $100 its cost plan assumes. The 19 November 2026 Investor Day and the…PLNTPlanet FitnessMedium Planet Fitness's third-quarter beat, raised sales outlook and five analyst target increases give the shares a modest edge over the S&P 500; flat membership of about 21.5 million means the New Year join season and the February 2027 report…PRCHPorch GroupMedium Porch Group's insurance fees beat in Q3 2026 and lifted 2026 adjusted EBITDA guidance to $135-140M, and the shares hit a 52-week high on 10 November 2026 despite CEO stock sales. Year-end Reciprocal surplus and the Q4 report around…PSIXPower Solutions InternationalMedium Power Solutions International's record third-quarter profit, raised second-half outlook and new multi-year engine supply deal support the shares beating the S&P 500. The fourth-quarter report, where management addresses 2027 data-center…PTLOPortillo'sMedium Portillo's turned same-restaurant sales positive and raised adjusted EBITDA guidance to $98–$101 million on 5 November 2026, leaving the shares modestly likelier than not to beat the S&P 500. Transactions still fell 0.7%, so the January…PUBMPubMaticMedium PubMatic's Q3 2026 beat, with revenue up 17% to $79.6 million and connected TV growth above 30%, supports a revenue recovery the shares have nearly priced back to their 52-week high; Q4 revenue of at least the $91 million guidance floor…PVLAPalvella TherapeuticsMedium Palvella Therapeutics has pulled back from its record close while the FDA reviews QTORIN rapamycin for a 28 February 2027 decision, with no adverse review news and $236.7 million in cash; review updates and the fourth-quarter Phase 3 start…RCELAvita MedicalMedium AVITA Medical's shares are modestly more likely than not to beat the S&P 500 after 53% revenue growth and a raised $92–94 million 2026 guide; the fourth-quarter report shows whether promised cash-flow breakeven arrives.RCLRoyal Caribbean GroupMedium Royal Caribbean Group's third-quarter beat, raised 2026 outlook and rising analyst targets give the shares a modestly better-than-even chance of beating the S&P 500, despite heavy director selling in November 2026. The fourth-quarter…RDVTRed VioletMedium Red Violet's identity-data business still grows faster than its costs, with third-quarter 2026 revenue up 20% and a 40% adjusted EBITDA margin, giving the shares modestly better than even odds of beating the S&P 500. The fourth-quarter…REALRealRealMedium The RealReal's 29 October 2026 beat and raise, with luxury-resale GMV up 23%, makes the shares modestly likely to beat the S&P 500; the fourth-quarter report must deliver the guided $27.5–29.0 million of adjusted EBITDA.REFReformationMedium Reformation's shares are modestly more likely than not to beat the S&P 500: revenue grows about 20% and the 2026 sales outlook was raised to $610–612 million. Holiday trading from 27 November 2026 and the estimated 26 January 2027 IPO…REGNRegeneron PharmaceuticalsMedium Regeneron's shares are modestly more likely than not to beat the S&P 500 because it now keeps its full Dupixent profit share, with EYLEA HD and Libtayo adding growth. The November 2026 cemdisiran FDA decision, the 4 December 2026 EYLEA HD…REPLReplimune GroupMedium Replimune's melanoma drug TUDRIQEV, first delivered on 6 October 2026, gives the shares a modest edge over the S&P 500 as early prescribing builds. The fiscal third-quarter report, expected around February 2027, carries the first sales…REZIResideo TechnologiesMedium Resideo Technologies is modestly more likely than not to beat the S&P 500 after a third-quarter beat in its first full quarter as a standalone controls maker. The fourth-quarter report expected in February 2027 shows whether its 6% core…RKLBRocket LabMedium Rocket Lab's record third-quarter revenue of $267.8 million and its $3.57 billion backlog give the shares a modestly better-than-even case against the S&P 500 over three months. A dated Neutron launch quarter and fourth-quarter revenue…RTXMedium RTX Corporation's record $340 billion backlog and raised 2026 guidance outweigh a defense budget now likely to slip into 2027; the 11 December 2026 funding deadline and the first 2027 guidance at the late-January report settle the case.SAROStandardAeroMedium StandardAero's engine-overhaul profits are growing faster than revenue: third-quarter 2026 adjusted EBITDA rose 15% and the company raised 2026 guidance again on 5 November 2026. The fourth-quarter report, expected around 26 February 2027,…SDGRSchrodingerMedium Schrödinger's software revenue returned to growth and its full-year contract-value guidance rose to $222–232 million, giving the shares a modest edge over the S&P 500. The fourth-quarter report, expected around late February 2027, settles…SEZLSezzleMedium Sezzle's third-quarter beat, with credit-loss provisions at 2.7% of transaction volume, 955,000 subscribers and a $7.20 2027 EPS target, gives Sezzle Inc. shares a modest edge over the S&P 500. Fourth-quarter credit, reported around late…SGSweetgreenMedium Sweetgreen's comparable sales turned positive in October, up about 5% after the cyclospora outbreak, which gives the shares a modest edge over the S&P 500. Fourth-quarter comparable sales, which management expects to grow about 4%, settle…SGHTSight SciencesMedium Sight Sciences' TearCare dry-eye treatment is becoming a second revenue line beside its OMNI glaucoma devices, giving the shares a modest edge over the S&P 500: third-quarter dry-eye sales rose 45% to $3.9 million, and UBS raised its…SHOPShopifyMedium Shopify's growth case holds after its third-quarter 2026 report, with revenue up 32% and low-thirties fourth-quarter guidance, though merchant sales growth slowed to 29%. The holiday sales tally around 1 December 2026 and the February 2027…SIBNSI-BONEMedium SI-BONE's recovery case holds after a third-quarter beat and a final 2027 Medicare office payment, giving its shares a modest edge over the S&P 500. Late-February results settle it by showing whether fourth-quarter growth topped 20%.SIGSignet JewelersMedium Signet Jewelers is earning more on flat sales after raising fiscal 2027 adjusted EPS guidance to $10.45–$12.15; its 2 December 2026 third-quarter report tests that range against an $11.70 Zacks consensus in its upper half.SLDESlide Insurance HoldingsMedium Slide Insurance is earning well ahead of plan on Florida homeowners policies and paying a $1.50 special dividend after raising 2026 net income guidance to $500–520 million. The fourth-quarter report, estimated around 25 February 2027,…SMGScotts Miracle-GroMedium Scotts Miracle-Gro's margin recovery gives the shares a modest edge: fiscal 2027 adjusted EPS guidance of $4.70 to $4.90 meets the $4.71 consensus despite about $100 million of commodity inflation. The late-January 2027 report and spring…SMMTSummit TherapeuticsMedium Summit Therapeutics' case rests on FDA approval of ivonescimab in EGFR-mutant lung cancer by the 14 November 2026 goal date. The agency's reading of a primary survival result with p=0.057 settles it, and the shares closed at $15.07 on 12…STGWStagwellMedium Stagwell's technology and data units are lifting profit faster than revenue, with third-quarter adjusted EBITDA up 25% on 10% revenue growth, giving the shares a modest edge. The February 2027 guidance, the first without election spending,…TDOCTeladoc HealthMedium Teladoc Health's Q3 2026 beat and fast-growing BetterHelp insurance revenue give the shares a modest edge over the S&P 500. The refinancing of $1.0 billion of notes due June 2027 and the Q4 report settle whether the turnaround holds.TLNTalen EnergyMedium Talen Energy's new seven-year Ohio capacity sale and its 2027 guidance of $2.5–2.85 billion adjusted EBITDA make the shares modestly more likely than not to beat the S&P 500. PJM's December 2026 capacity auction will test whether…TMOThermo Fisher ScientificMedium Thermo Fisher Scientific's 6% third-quarter organic growth, raised 2026 outlook and $5 billion buyback give the shares a modest edge over the S&P 500. The late-January 2027 report and first 2027 guidance decide whether that growth holds.TREELendingTreeMedium LendingTree's insurance-led growth, falling debt and first planned buyback since 2022 give its shares a modest edge over the S&P 500 even after they gave back part of the post-report rally. The fourth-quarter report settles whether the…TSMTaiwan Semiconductor ManufacturingMedium Taiwan Semiconductor Manufacturing's record October sales of NT$586.89 billion put fourth-quarter revenue on pace for the top of guidance, giving the shares a modest edge over the S&P 500. Nvidia's 17 November 2026 report and TSMC's…TTEKTetra TechMedium Tetra Tech's $4.67 billion backlog, up 13%, and fiscal 2027 guidance above consensus give it a modest edge over the S&P 500. The late-January 2027 first-quarter report shows whether net revenue lands inside the $1.040–$1.080 billion…TWTradeweb MarketsMedium Tradeweb Markets' 26.3% October volume growth points to fourth-quarter revenue growth above the third quarter's 14.9%. The November volume report around 4 December 2026 and fourth-quarter results show whether revenue keeps pace as credit…TXNTexas InstrumentsMedium Texas Instruments' analog upturn, driven by data-center demand and pricing that lifted third-quarter 2026 revenue 28%, gives the shares a modest edge over the S&P 500. The late-January 2027 report, measured against the $5.80–6.30 billion…UBERUber TechnologiesMedium Uber Technologies shares are modestly more likely to beat the S&P 500: third-quarter bookings rose 20% with profit growing faster, yet the stock sits 25.7% below its high. The early-February 2027 report shows whether bookings growth holds…UFPTUFP TechnologiesMedium UFP Technologies is growing above its own target, with 11.1% Q3 2026 organic growth against a 6%–9% goal, while delayed Dominican Republic transfers hold margins back. The Q4 report, expected around March 2027, shows whether growth stays…UNHUnitedHealth GroupMedium UnitedHealth Group's earnings recovery, with 2026 adjusted EPS guided to at least $20.50 and a buyback widened by 50 million shares, gives the shares a modest edge over the S&P 500; the 7 December 2026 Medicare enrollment close and the…UPBDUpbound GroupMedium Upbound Group's tighter Acima lending is lifting profit and cash flow as lease volume shrinks, Brigit adds growth, and executives kept buying stock; the late-February 2027 Q4 report shows whether Acima volume levels off as guided.VCELVericelMedium Vericel's knee-cartilage implant MACI is growing above 20% a year and the 5 November 2026 report raised 2026 revenue guidance to $344–346 million. The fourth-quarter report settles the case by showing whether MACI reaches about $102…VEEVVeeva SystemsMedium Veeva Systems is modestly more likely than not to beat the S&P 500, after it said its fiscal third quarter would meet or exceed guidance and ten analyst firms raised targets; the 3 December 2026 report shows whether revenue clears $932–935…VEONMedium VEON raised the floor of its 2026 revenue and EBITDA growth guidance on 6 November 2026 as digital profit outgrew digital sales, backing its shift from mobile carrier to digital operator; the 16 November 2026 Capital Markets Day tests the…VERXVertexMedium Vertex's 4 November 2026 third-quarter beat, with cloud revenue up 20.4% and net revenue retention up to 106%, gives the tax-software shares a modest edge over the S&P 500; the fourth-quarter report, expected around late February 2027,…VIAVia TransportationMedium Via Transportation's shares are modestly more likely than not to beat the S&P 500, after a third-quarter beat, a raised 2026 revenue guide and five target increases; the fourth-quarter report, expected around late February 2027, settles it…VRDNViridian TherapeuticsMedium Viridian Therapeutics' shares are modestly more likely than not to beat the S&P 500: Lumvoa's $24.7 million first full quarter beat estimates and VRDN-008 data on 9 November 2026 added an autoimmune program. Fourth-quarter Lumvoa sales,…VSTVistraMedium Vistra Corp. shares lean toward beating the S&P 500 on 2027 adjusted EBITDA guidance of $7.7–8.5 billion. Texas data-center policy settles it: the December 2026 grid audit and the new governor's first moves after 19 January 2027.VYXNCR VoyixMedium NCR Voyix's shares have a modest edge over the S&P 500 because large grocers and restaurant chains are signing onto its cloud platform and its margins are rising. The fourth-quarter report, expected in February 2027, shows whether 2026…XNCRXencorMedium Xencor's shares hold a modest edge over the S&P 500 on XmAb819's 45.5% confirmed response rate in advanced kidney cancer and cash funding into 2029. First-half 2027 data in at least 20 patients at 400 mcg/kg and the FDA's view on…ZLABZai LabMedium Zai Lab's shares are modestly more likely to beat the S&P 500 over three months on zoci, its DLL3 cancer drug with an 81.8% first-line response rate; a global first-line Phase 3 start announced by 31 December 2026 settles it.ZVRAZevra TherapeuticsMedium Zevra Therapeutics is modestly more likely to beat the S&P 500 over three months: MIPLYFFA sold $34.0 million in the third quarter of 2026 and the company is profitable; the EMA re-examination of arimoclomol, guided to the fourth quarter,…AALAmerican Airlines GroupLow American Airlines shares are more likely to lag the S&P 500 over three months because jet fuel near $4.70 a gallon is consuming record revenue; the fourth-quarter report, expected in late January 2027, shows whether the guided loss of…ABCLAbCellera BiologicsLow AbCellera's shares look more likely to lag the S&P 500 over three months, because the case rests on unproven repeat dosing of ABCL635, its monthly hot-flash injectable. The open-label extension data, guided for late 2026 to early 2027,…ACNAccentureLow Accenture's shares are more likely to lag the S&P 500 over the next three months because their $249.95 close on 12 November 2026 already sits above the roughly $230 average analyst target. The fiscal first-quarter 2027 report, expected…ADBEAdobeLow Adobe's shares are more likely to lag the S&P 500 because analysts expect its recurring-revenue growth to slow sharply in fiscal 2027 and its MAX AI launches carry no disclosed revenue. The 9 December report and fiscal 2027 guidance show…ADTLow ADT Inc. trades as a pending $10.00-per-share cash buyout by Thrive Holdings, so its shares are more likely to lag the S&P 500 than lead it. A rival bid before the go-shop window closes on 28 November 2026 is the one event that would…AFRMAffirm HoldingsLow Affirm Holdings' shares are more likely to lag the S&P 500: growth beat in the 5 November 2026 report, but delinquency rose to 2.9% and funding costs climbed. The February 2027 holiday-quarter report shows whether credit steadies.AMATApplied MaterialsLow Applied Materials looks more likely to lag the S&P 500 over the next three months: a 12 November 2026 outlook for more than 30% equipment-industry growth in 2027 did not stop a fall, as 11 brokers cut targets on sector valuations. Nvidia's…AMNAMN Healthcare ServicesLow AMN Healthcare Services is more likely to lag the S&P 500 because its fourth-quarter outlook cuts strike revenue to $5 million from $59 million and resets margins lower; the report expected around February 2027 shows whether nurse staffing…AMPLAmplitudeLow Amplitude's shares are more likely to lag the S&P 500: its 4 November 2026 beat-and-raise left net retention flat at 103% and gross margin lower, and the shares fell the next day. The fourth-quarter report, expected in February 2027,…ARMArm HoldingsLow Arm Holdings shares look more likely to lag the S&P 500 because royalty growth slowed to 8% and is guided to low single digits. Judge Noreika's ruling on Qualcomm's royalty suspension and the report due in early February 2027 settle the…ARRYArray TechnologiesLow Array Technologies' shares are more likely to lag the S&P 500 while they trade on the all-stock Shoals merger after a cut to 2026 guidance; the S-4 filing, both shareholder votes and a first-quarter-2027 closing decide whether the $2.2–2.4…ASMLASML HoldingLow ASML Holding's shares look more likely to lag the S&P 500 than lead it while chip stocks reprice 2027 US data-centre spending risk, despite supply that trails demand through 2028. Nvidia's 17 November 2026 report and ASML's late-January…ASTSAST SpaceMobileLow AST SpaceMobile's shares look more likely to lag the S&P 500 than lead it after a third-quarter revenue miss and a 45-satellite target pushed to mid-2027. Shipment of BlueBirds 17 to 19 by the end of November 2026 and launches of BlueBirds…AXPAmerican ExpressLow American Express shares are more likely to lag the S&P 500 over the next three months, as card spending growth slowed to 8% and the 2026 guidance raise rests on a one-time gain; the fourth-quarter report and 2027 outlook, expected in late…AZOAutoZoneLow AutoZone is more likely to lag the S&P 500 over three months: its 1.6% domestic same-store sales growth trails O'Reilly's 7.2%, and its latest profit gain leaned on tariff refunds. The 8 December 2026 first-quarter report shows whether…BABoeingLow Boeing's shares look more likely to lag the S&P 500 because 737 MAX deliveries fell to 32 in October 2026 and its airplane unit is cutting 5% of staff. The November delivery release (~8 December 2026) and 777X engine-seal and ETOPS…BABAAlibaba Group HoldingLow Alibaba's shares are more likely to lag the S&P 500 into the 19 November 2026 September-quarter report: cloud revenue grew 45% in the June quarter, but chip supply, Qwen pricing and funding costs are unresolved. The report shows whether…BACBank of AmericaLow Bank of America's shares look more likely to lag the S&P 500 as weak fees and trading, a $1.2 billion penalty and falling broker targets outweigh 8% lending-income growth; the 15 January 2027 fourth-quarter report shows whether fees…BBWIBath & Body WorksLow Bath & Body Works shares are more likely to lag the S&P 500 because analysts already expect third-quarter earnings above the company's own guidance; the 19 November 2026 Q3 report settles whether sales and the roughly $650 million…BEBloom EnergyLow Bloom Energy shares look more likely to lag the S&P 500 over three months: the 11 November rebound followed CoreWeave's results, while Oracle's 2.4 GW Project Jupiter still lacks its New Mexico air permit. The hearing that opens 7 December…BETABeta TechnologiesLow Beta Technologies' shares look more likely to lag the S&P 500, because Jefferies now models first CX300 deliveries in 2028 and fourth-quarter revenue is guided below the third quarter's. The FAA's pilot-program pathway and the early-2027…BETRBetter Home & Finance HoldingLow Better Home & Finance shares are more likely to lag the S&P 500 over three months: volume fell from $496 million in July to $345 million in October and cash is shrinking. The weekly Better 2.0 scorecards will show whether the cost cuts…BIDUBaiduLow Baidu's shrinking search advertising still outweighs its fast-growing AI cloud, so the ADS is more likely to lag the S&P 500 over three months; the third-quarter report on 16 November 2026 shows whether the advertising decline narrows.BMBLBumbleLow Bumble's shares are likely to trail the S&P 500 because they trade as a pending $6.05-per-share cash takeover by Ithaca Holdings, closing at $5.99 on 11 November 2026. Antitrust clearance and the Schedule 14C closing timeline decide when…BOBSBobs Discount FurnitureLow Bob's Discount Furniture shares look more likely to lag the S&P 500 as a diesel-driven gross margin cut and a 30% furniture tariff from 1 January 2027 weigh on a stock already near analyst targets. The fourth-quarter report settles whether…BRK.BBerkshire HathawayLow Berkshire Hathaway's class B shares look more likely to lag than lead the S&P 500: third-quarter operating earnings fell 5.8% while the shares hit a record $589.83, far above the $496–$507 Berkshire paid for buybacks. Whether repurchases…BRUNBoost RunLow Boost Run's shares are more likely to lag the S&P 500 over the next three months: third-quarter 2026 revenue missed, a $13 million-a-month Georgia project slipped to 2027, and its 2027 hardware plan far exceeds its cash. The end-November…BRZEBrazeLow Salesforce's agreed $47.50-per-share cash takeover of Braze caps the shares just under the offer, so they are more likely to lag the S&P 500 than lead it over three months. The US antitrust review, the stockholder vote or a rival bid…BSXBoston ScientificLow Boston Scientific shares are more likely to lag the S&P 500 over three months: a cyberattack, falling Watchman sales and lost ablation share turned fourth-quarter sales guidance negative. The fourth-quarter report expected around 4…BZKanzhunLow Kanzhun (BOSS Zhipin) shares are more likely to lag the S&P 500 over three months after an unexplained fall to a record-low $12.49 close on 12 November 2026; the third-quarter 2026 report, expected in late November 2026, shows whether…CAPRCapricor TherapeuticsLow Capricor Therapeutics' shares are more likely to lag the S&P 500 because deramiocel's approval faces an FDA panel that voted 9-3 against its evidence in July 2026. The FDA's action on the narrowed application, due by 22 November 2026,…CARSCars.comLow Cars.com's earnings are growing on cost cuts and buybacks while revenue stays flat, and the shares already trade near analyst targets, so they are more likely to lag the S&P 500 over three months; the late-February 2027 fourth-quarter…CARTMaplebearLow Maplebear, Instacart's parent, looks likely to lag the S&P 500 because DoorDash's $65.00-a-share offer caps the gain while antitrust review may run into 2028. The first federal step on the merger filing settles the case.CATCaterpillarLow Caterpillar's shares look more likely to lag the S&P 500, as political risk to data-center building and margins near the bottom of target outweigh a record $78 billion backlog. The 2027 outlook, expected around 2 February 2027, shows…CCJCamecoLow Cameco's shares are more likely to lag the S&P 500 because record uranium contract prices have not yet reached its earnings, with third-quarter adjusted profit at nil on 30 October 2026. The full-year report expected in February 2027…CDNLCardinal Infrastructure GroupLow Cardinal Infrastructure Group's shares are more likely to lag the S&P 500 over three months after a 4.2% third-quarter margin, withdrawn 2026 guidance and a departing CFO. The fourth-quarter report, expected around March 2027, shows…CERTCertaraLow Certara's software sales have re-accelerated, but at $11.73 the shares already trade near analysts' raised targets, so they are more likely to lag the S&P 500 over the next three months. The fourth-quarter report and 2027 outlook, expected…CHPTChargePoint HoldingsLow ChargePoint shares are more likely to lag the S&P 500 after a 102% three-month rally that outran a business guiding third-quarter revenue below its second quarter. ChargePoint's early-December third-quarter report shows whether revenue and…CLVTClarivateLow Clarivate's shares are more likely to lag the S&P 500 over the next three months: the $533 million debt tender that settled on 13 November 2026 is priced in, and 1.3% organic recurring growth is too slow to lift the stock before the 2027…COINCoinbase GlobalLow Coinbase Global shares look more likely to lag the S&P 500 because trading revenue is shrinking faster than new licenses add income. The fourth-quarter report, expected about mid-February 2027, tests the $550–630 million services guide.COPConocoPhillipsLow ConocoPhillips is more likely to lag the S&P 500 over three months because its gains rest on a war-lifted crude price; the OPEC+ meeting on 29 November 2026 tests that premium.COTYLow Coty Inc.'s debt cut and Q1 FY27 beat have lifted the shares to $4.06, above every analyst target, while earnings are still guided lower; the Consumer Beauty review due by 31 December 2026 decides whether earnings support that price.CRMSalesforceLow Salesforce shares look more likely to lag the S&P 500, as seven acquisitions and S&P's 4 November 2026 credit cut cloud organic growth behind its AI-agent revenue. The 2 December 2026 third-quarter report shows whether cRPO growth beats…CRMDCorMedixLow CorMedix shares are more likely to lag the S&P 500 over three months because its DefenCath drug has lost most of its Medicare premium and 2027 DefenCath guidance is suspended. A separate Medicare Advantage payment deal, which management…CRSPCRISPR TherapeuticsLow CRISPR Therapeutics shares are more likely to lag the S&P 500 over three months: they hit a 52-week closing low of $42.62 on 12 November 2026 despite strong CTX310 data, and December's zugo-cel data at ASH is the next test.CRWDCrowdStrike HoldingsLow CrowdStrike's shares are more likely to lag the S&P 500 over the next three months because at about 156 times forward earnings they already price in fast growth. The 1 December 2026 report settles it by showing whether net new annual…CSCOCisco SystemsLow Cisco Systems' shares look more likely to lag the S&P 500 over three months because product order growth slowed to 21% from 35% despite a raised outlook; the second-quarter report expected in mid-February 2027 shows whether orders recover.CTOCTO Realty GrowthLow CTO Realty Growth is more likely to lag the S&P 500 over three months: per-share earnings are rising, but the shares trade below its 2026 stock-sale price and leverage is climbing; the fourth-quarter report, expected in February 2027,…CTVACortevaLow Corteva, now a pure crop-protection company, is more likely to lag the S&P 500 after cutting its 2026 profit outlook on 11 November 2026 over a materially weaker Brazil. The early-2027 fourth-quarter report and the first 2027 outlook show…CVXChevronLow Chevron's shares are more likely to lag the S&P 500 over the next three months as Brent fell to $91.49 on 10 November 2026 and OPEC output neared prewar levels. The fourth-quarter report, around 30 January 2027, shows whether buybacks rise…CXMSprinklrLow Sprinklr's shares look more likely to lag the S&P 500, because an AI-agent rally has outrun a business whose revenue grew 1% last quarter. The third-quarter report on 2 December 2026 shows whether subscription growth can support the price.DASHDoorDashLow DoorDash shares are more likely to lag the S&P 500 over three months: a $17 billion Instacart deal facing a review that may run to 2028 and a flat fourth-quarter profit guide outweigh record results; the February 2027 report is the next…DEDeereLow Deere & Company is more likely to lag the S&P 500 over three months because its shares already price in a 29% earnings rebound for fiscal 2027; the 25 November 2026 fourth-quarter report and first 2027 outlook show whether the company's…DELLDell TechnologiesLow Dell Technologies' shares look more likely to lag the S&P 500 while AI-spending doubts, data-center politics and memory costs drive the stock; the 24 November 2026 fiscal third-quarter report tests the 15.0% server margin and a $50.63…DISWalt DisneyLow The Walt Disney Company's shares look more likely to trail the S&P 500 than lead it, because a 14.2% three-month gain already prices in parks, streaming and cost-cut gains. The 17 November 2026 fiscal Q4 report shows whether fiscal 2027…DNUTKrispy KremeLow Krispy Kreme's shares are more likely to lag the S&P 500 because its 5 November 2026 earnings beat has not yet turned into cash: free cash flow was negative $10.0 million through nine months and net leverage was 5.5 times. The…DXCDXC TechnologyLow DXC Technology's shares are more likely to lag the S&P 500 because they trade above every post-results analyst target while the insurance-unit sale remains unsigned. A signed deal and its price settle the case.ENGSEnergys GroupLow Energys Group's shares fell 86% in one session to a $0.69 close on 11 November 2026 with no company explanation and are more likely to lag the S&P 500; the delayed fiscal 2026 annual report shows whether a projected 52% revenue gain holds…ENVXEnovixLow Enovix shares are more likely to lag the S&P 500 over three months after the company dropped smartphone field testing and guided fourth-quarter sales below the third quarter's on 12 November 2026. The fourth-quarter report, expected in…ETEnergy Transfer LP Common UnitsLow Energy Transfer's units are more likely to lag the S&P 500 over three months because the raised 2026 outlook rests on commodity gains and one-time items while spending climbs. The fourth-quarter report expected in mid-February 2027, with…FIGRFigure Technology SolutionsLow Figure Technology Solutions shares are more likely to lag the S&P 500 because the company guided its fourth-quarter take rate down to 3.1%–3.4% on 12 November 2026 despite beating forecasts; operating data expected around 7 January 2027…FRMIFermiLow Fermi Inc. shares are more likely to lag the S&P 500 over three months: a $200 million hyperscaler prepayment gives Project Matador a customer, but the 600-megawatt lease is unsigned and the 12 November 2026 10-Q flags going-concern doubt.…FRVOFervo EnergyLow Fervo Energy shares look more likely to lag the S&P 500 over three months: IPO lock-up supply and broker target cuts outweigh an $11.9 billion backlog. Cape Station's GeoBlocks 2 and 3 reaching commercial operation by 1 January 2027 decide…FTREFortrea HoldingsLow Fortrea's shares are more likely to lag the S&P 500: margins are improving, but a $558 million backlog cut clouds 2027 revenue. Backlog growth from $7,316 million at the fourth-quarter report settles the case.GEGE AerospaceLow GE Aerospace shares are more likely to trail the S&P 500 than lead: record China orders lifted them, but services and LEAP delivery growth slowed in the third quarter. FAA approval of the GE9X mid-seal and 2027 guidance around 22 January…GLOBGlobantLow Globant's shares are more likely to lag the S&P 500 because the price has run ahead of flat revenue guidance and Guggenheim downgraded them on 11 November 2026 over weak bookings; the 19 November 2026 third-quarter report shows whether…GOOGAlphabetLow Alphabet's shares are more likely to lag the S&P 500 as 2027 spending above $300 billion and negative free cash flow outweigh Cloud revenue that doubled to $30.7 billion; the fourth-quarter report tests whether the $561 billion Cloud…GOOGLAlphabetLow Alphabet's shares look more likely to lag the S&P 500 because Google Cloud's 103% growth has not yet paid for AI spending that turned free cash flow negative. Anthropic's IPO pricing, expected in the week of 16 November 2026, and the 2027…GRALGRAILLow GRAIL's shares are more likely to lag the S&P 500 over three months: after a 78.8% three-month rise, approval of the Galleri cancer test looks largely priced in while the company cut its 2026 Galleri revenue outlook and per-test prices…GSGoldman Sachs GroupLow Goldman Sachs' shares look more likely to lag the S&P 500 over the next three months: the Anthropic IPO it co-leads is largely priced in, while Fed rate-increase risk and a smaller fee backlog weigh on 2027 fees. The fourth-quarter report,…HALOHalozyme TherapeuticsLow Halozyme Therapeutics' shares are more likely to lag the S&P 500 after two downgrades in a week shifted the debate to royalty-rate step-downs from 2028. The 19 November 2026 German Keytruda SC appeal hearing and 2027 guidance are the next…HAYWHayward HoldingsLow Hayward Holdings' raised 2026 guidance is already priced into shares trading above most broker targets, so they are more likely to lag the S&P 500; the late-February 2027 fourth-quarter report shows whether early-buy orders become sales.HDHome DepotLow Home Depot's shares have climbed on falling mortgage rates while its customer traffic still shrinks, so they look more likely to lag the S&P 500; the 17 November 2026 third-quarter report shows whether guidance and transactions back the…HELEHelen of TroyLow Helen of Troy's shares are more likely to lag the S&P 500 because the $37.98 close on 11 November 2026 already tops Empower Brands' rejected $37.00 offer. A higher signed deal, or a stalemate at the report due around 8 January 2027,…HIMSHims & Hers HealthLow Hims & Hers Health shares are more likely to lag the S&P 500 after a 9 November 2026 report showing 57% gross margin and a flat fourth-quarter revenue guide. November weight-loss billing data and early Lilly drug sales show whether growth…HOODRobinhood MarketsLow Robinhood Markets' event contracts are growing while crypto volume fell 21% in October and stock and options trading stalled, so the shares are more likely to lag the S&P 500; November data and the February 2027 fourth-quarter report…HRIHerc HoldingsLow Herc Holdings looks more likely to lag the S&P 500 over three months because its raised 2026 guide is largely priced in after shares rebounded to $173.90 on 11 November 2026 without new company news. The fourth-quarter report, expected…HUBSHubSpotLow HubSpot shares are more likely to lag the S&P 500: co-founder Brian Halligan's return as CEO on 12 November 2026 left the roughly 12% fourth-quarter growth guide unchanged. The February 2027 report and 2027 outlook settle it.IBMInternational Business MachinesLow International Business Machines (IBM) shares look more likely to lag the S&P 500 over three months because faster software growth leans on the Confluent deal while the 4%–5% 2026 revenue outlook stayed put. The full-year report expected…IBRXImmunityBioLow ImmunityBio's third-quarter Anktiva revenue of $48.7 million fell below the second quarter's $50.7 million, and the shares are more likely to lag the S&P 500 until detailed QUILT-2.005 efficacy data and a fourth-quarter revenue rebound…IBTAIbottaLow Ibotta's Q3 2026 beat is already in the price, and Koch's investment vehicle sold shares into the rally, so the stock is more likely to lag the S&P 500 over three months. The Q4 2026 report decides whether growth beats the $94–98 million…INTCIntelLow Intel's shares look more likely to lag the S&P 500 than lead it over the next three months, because the PC slump, Israel fab costs and cash burn are unresolved and Bank of America cut its target to $80 on 12 November 2026. Nvidia's 17…IONQLow IonQ's shares are more likely to lag the S&P 500 over three months as a sudden finance-chief exit and 34.6 million newly registered resale shares add to widening losses despite a raised $505–515 million 2026 revenue outlook. Gary Merrill's…IRENLow IREN Limited's shares look more likely to lag the S&P 500, because its AI cloud ramp is behind its own $4 billion operating revenue-rate target while Microsoft reassesses neocloud deals. Operating annual recurring revenue reported against…ISRGIntuitive SurgicalLow Intuitive Surgical's shares look more likely to lag the S&P 500 because US procedure growth slowed to 10% and instrument revenue per procedure is set to fall 3%–5% from 2027. The mid-January 2027 preliminary procedure count will show…JNJJohnson & JohnsonLow Johnson & Johnson's drug approvals keep coming, but weak medical devices and $1.36 per share of 2027 deal dilution leave the shares more likely to lag the S&P 500. The 8 December 2026 business review and January 2027 guidance settle it.JPMJPMorgan ChaseLow JPMorgan Chase's shares look more likely to trail the S&P 500 over three months after a third-quarter miss, a roughly 90% buyback cut and a reported Senate Epstein review; the 9 December 2026 CFO update and 14 January 2027 report decide it.KDKyndryl HoldingsLow Kyndryl's shares are more likely to lag the S&P 500 because profit and signings improved but free cash flow did not; the fiscal third-quarter report, around early February 2027, shows whether the $400–500 million cash target holds.KIDSOrthoPediatricsLow OrthoPediatrics shares are more likely to lag the S&P 500 because the $33.67 close on 11 November 2026 sits above six of seven post-report analyst targets despite 19% sales growth. Preliminary fourth-quarter revenue, expected about…KMPRKemperLow Kemper Corporation's third-quarter 2026 profit came with a personal auto book down about 10% in the quarter and an underlying combined ratio still above 100%. After a 30.7% three-month rise, the shares are more likely to lag the S&P 500…KOCoca-ColaLow Coca-Cola's shares are more likely to lag the S&P 500: at about 28 times forward earnings and above the average analyst target, the raised 2026 outlook looks priced in. The fourth-quarter report with first 2027 guidance, expected around 10…KODKodiak SciencesLow Kodiak Sciences' shares look more likely to lag the S&P 500 after a 161.8% three-month run that prices in the DAYBREAK win while share sales have begun. The PEAK topline, guided for December 2026, settles it.KSSKohlsLow Kohl's shares are more likely to lag the S&P 500, trading above the $17.25 consensus target on one upgrade and a refund-aided guidance raise; the Q3 report expected around 24 November 2026 shows whether $1.80–$2.40 EPS guidance holds.LACLithium AmericasLow Lithium Americas' shares are more likely to lag the S&P 500 because its 11 November 2026 Thacker Pass cost increase of $900 million to $3.83 billion adds to funding needs while dilution continues; year-end 2026 power energization and final…LIFEEthos TechnologiesLow Ethos Technologies' shares look more likely to lag the S&P 500: record third-quarter growth came from the short-seller-disputed agency channel while receivables and insider sales kept rising. The next customer-concentration disclosure and…LITELumentum HoldingsLow Lumentum Holdings' shares look more likely to lag the S&P 500 because a fixed 4.500-share Marvell merger ties them to Marvell's stock more than to Lumentum's growth. Marvell's 1 December 2026 quarterly report is the next test.LMNDLemonadeLow Lemonade's shares are more likely to lag the S&P 500 as a 65% loss ratio and a new S-3 registration offset its Q4 2026 profit target; the 17 November 2026 investor day and Q4 results settle it.LRCXLam ResearchLow Lam Research shares look more likely to lag the S&P 500 over the next three months because a buyback-led rebound still runs ahead of unresolved 2027 chip-equipment demand. Applied Materials' 12 November 2026 beat gave no 2027 figure; Lam's…METAMeta PlatformsLow Meta Platforms shares look more likely to lag the S&P 500 over three months: 26% ad growth faces $25 billion of forward-sale stock, new bonds and a roughly $60 billion Class C stock program that can start on 19 January 2027. Fourth-quarter…MODModine ManufacturingLow Modine Manufacturing's shares are more likely to lag the S&P 500 over three months: data-center sales rose 95% in the quarter to 30 September 2026, but their gross margin fell to 19.7%. The 18 November 2026 Investor Day, where management…MPMP MaterialsLow MP Materials shares look more likely to lag the S&P 500 over three months because General Motors magnet volumes start small and analysts keep cutting targets. The expected Trump–Xi meeting at APEC on 18 November 2026 and fourth-quarter…MRNAModernaLow Moderna's shares are more likely to lag the S&P 500 over three months: a 246.5% three-month gain already prices its surprise profit and melanoma vaccine, and 2027 guidance waits for the fourth-quarter report. The 18 November 2026 Jefferies…MRVLMarvell TechnologyLow Marvell Technology shares are more likely to lag the S&P 500 over the next three months because merger arbitrage gives its $115 billion all-stock Lumentum deal only even odds, leaving an overhang until 2028. The 1 December 2026 fiscal…MSTRStrategyLow Strategy Inc.'s common shares are more likely to lag the S&P 500: MSCI confirmed on 11 November 2026 that it will delete the stock at the 30 November close, and bitcoin trades below Strategy's $75,456 average cost. Weekly 8-K filings show…NBISNebius GroupLow Nebius Group's shares are more likely to lag the S&P 500 over three months because its 12 November 2026 report pushed Microsoft capacity into 2027 and raised 2026 spending to about $27 billion. The fourth-quarter report, expected around…NFLXNetflixLow Netflix's shares are more likely to lag the S&P 500 than lead it while members use the service less and its 2026 ad target sits cut; the fourth-quarter report and 2027 outlook, expected around 20 January 2027, decide whether engagement has…NIOLow NIO Inc. shares are more likely to lag the S&P 500 over three months because October deliveries fell 15.23% from a year earlier as ONVO collapsed. The third-quarter report, expected around 24 November 2026, and November deliveries in early…NKENikeLow Nike's shares are more likely to lag the S&P 500 over the next three months because revenue is still falling and analysts keep trimming targets; the 17 November 2026 Investor Day presentations and the December quarterly report show whether…NOWServiceNowLow ServiceNow's shares are more likely to lag the S&P 500 into the January 2027 report as slowing backlog growth and AI-competition fears outweigh a third-quarter beat. Fourth-quarter cRPO growth against the 18.5% guide decides the case.NRDSNerdWalletLow NerdWallet's shares are more likely to lag the S&P 500: its 5 November 2026 outlook guided fourth-quarter revenue down 13% with no fix date for auto insurance. The fourth-quarter report, estimated for late February 2027, shows whether 2027…NTRANateraLow Natera's shares are more likely to lag the S&P 500 into early 2027, because an abrupt CEO change on 5 November 2026 outweighed a revenue beat and raised guidance. The Q4 report, estimated for late February 2027, tests Signatera growth…NUNu HoldingsLow Nu Holdings shares are more likely to lag the S&P 500 over the next three months, as rising 90-day delinquencies and a post-election Brazil discount outweigh record profit. The 8 December 2026 Investor Day is the next test of that view.NVDANVIDIALow NVIDIA's shares are more likely to lag the S&P 500 over the next three months because Jensen Huang's 12 November 2026 resignation left an interim CEO, an open board investigation and seven broker downgrades. The 17 November 2026 quarterly…OKLOLow Oklo Inc. shares lean toward lagging the S&P 500 because its first Aurora plant still has no published cost and the company keeps selling stock. A disclosed plant cost and a quarter of slower share issuance would show that view wrong.ONDSOndasLow Ondas Inc. shares are more likely to lag the S&P 500 over three months: the 12 November 2026 report beat on revenue but halved margins and widened losses, and the fourth-quarter 2026 report, expected around March 2027, settles whether…OPCHOption Care HealthLow Option Care Health's $32.05-per-share cash sale to CD&R and McKesson caps the shares, which closed at $31.70 on 11 November 2026, so they are more likely to lag than lead the S&P 500. The 3 December 2026 antitrust waiting-period expiry and…ORCLOracleLow Oracle's shares look more likely to lag the S&P 500 over the next three months, as Microsoft's exit from rented capacity, a scrapped Tencent lease and heavy cash burn outweigh a peer-led rebound. The fiscal second-quarter 2027 report,…OSPNOneSpanLow OneSpan's move from hardware tokens to subscription software is working, but its guidance implies a slower fourth quarter after a 32.1% three-month rise, so the shares are more likely to lag the S&P 500. The report expected in late…OSWOneSpaWorld HoldingsLow OneSpaWorld, the spa operator on most large cruise ships, raised 2026 guidance but its shares already trade near analysts' targets and are more likely to lag the S&P 500; Carnival's December outlook and the late-February report decide it.PANWPalo Alto NetworksLow Palo Alto Networks shares are more likely to lag the S&P 500 until AI security demand lifts its $14.10B–$14.20B fiscal 2027 revenue outlook; the 18 November 2026 fiscal Q1 report settles it. Jefferies cut its target to $400 from $450 on 12…PCRXPacira BioSciencesLow Pacira BioSciences trades as a pending takeover pinned near Viatris's $36.50 cash offer, so the shares are more likely to lag the S&P 500 than lead it. The tender offer expiring on 16 November 2026, with antitrust clearance already…PDPagerDutyLow PagerDuty's shares are more likely to lag the S&P 500 over three months because a 32.1% three-month rally has run ahead of revenue growth of 0.8%. Fiscal third-quarter results, expected around 24 November 2026, test whether revenue and 98%…PEPPepsiCoLow PepsiCo shares look more likely to lag the S&P 500 over three months because North American snack profit and drink volume are shrinking while the stock has already climbed back to its 200-day average. The fourth-quarter report and first…PLTRPalantir TechnologiesLow Palantir Technologies looks more likely to lag the S&P 500 over three months because contract signings grew only 6% in the third quarter while revenue grew 96%; the fourth-quarter report, expected around 1 February 2027, shows whether…PLUGPlug PowerLow Plug Power's record-low $28 million Q3 2026 cash usage is real progress, but gross margin of about −3% was worse than Q2's −0.9%; Q4 targets of positive adjusted earnings and flat cash usage settle the next read.POOLLow Pool Corporation's shares closed at $221.05 on 9 November 2026, above the average analyst target after a third quarter of flat EPS, so they look more likely to lag the S&P 500 than lead it. The February 2027 report and its 2027 outlook…PSNLPersonalisLow Personalis trades as a fixed $16.25-per-share claim on Tempus AI's agreed takeover, so the shares are more likely to lag the S&P 500 than lead it; the 30 November 2026 stockholder vote and the closing settle it.PTCLow PTC Inc. is pinned just below Schneider Electric's $205-per-share cash offer, which the buyer called best and final, so the shares are more likely to lag the S&P 500 than lead it. Antitrust and CFIUS reviews, the shareholder vote and a…PZZAPapa John's InternationalLow Papa John's shares are more likely to lag the S&P 500 over the next three months: North America comparable sales fell 8.3% in the third quarter of 2026 and the 2026 outlook was cut again. The fourth-quarter report in late February 2027…QBTSD-Wave QuantumLow D-Wave Quantum's shares are more likely to lag the S&P 500 over three months because third-quarter orders fell to $1.9 million and five brokers cut targets on 11 November 2026. The fourth-quarter report, expected around 26 February 2027,…QCOMQUALCOMMLow Qualcomm's shares are more likely to lag the S&P 500 over three months: handset revenue fell 26% and the December-quarter chip margin is guided to 20% to 22% while data-center revenue is still small. The early-February 2027 report shows…QDELQuidelOrthoLow QuidelOrtho's shares are more likely to lag the S&P 500: third-quarter revenue fell 11.6% and net leverage rose to 4.5 times while the point-of-care sale meant to cut $2.94B of borrowings is still unsigned. A signed deal or the…RDDTRedditLow Reddit, Inc. shares are more likely to lag the S&P 500: falling search traffic threatens its daily user count despite 53% revenue growth. The February 2027 fourth-quarter report settles it.RGTIRigetti ComputingLow Rigetti Computing's shares look more likely to lag the S&P 500 after third-quarter 2026 revenue of $1.41 million missed a $3.52 million consensus; India's C-DAC accepting its 108-qubit system by 31 December 2026 decides whether the roughly…RIGTransoceanLow Transocean's shares are more likely to lag the S&P 500: its roughly $8 billion offshore-rig backlog has not lifted earnings, and 2027 revenue is guided flat at $3.85–4.0 billion. The 24 November 2026 Valaris votes and the deal's targeted 1…RNGRingCentralLow RingCentral's shares look more likely to lag the S&P 500 than lead it because software-sector selling has outweighed a third-quarter beat. The fourth-quarter report expected around 19 February 2027 settles whether revenue growth moves past…RPDRapid7Low Rapid7's shares look more likely to lag the S&P 500: cost cuts drove a third-quarter profit beat on 4 November 2026, but the company guides recurring revenue lower again for the fourth quarter. The February 2027 report and first 2027…RRCRange ResourcesLow Range Resources is likely to lag the S&P 500 because its shares now trade as 0.987 EQT shares under EQT's all-stock takeover, with the premium priced in; EQT's share price, gas prices and the shareholder votes before a first-quarter 2027…RXOLow RXO, Inc. is likely to lag the S&P 500 because C.H. Robinson's pending $17.25-cash-plus-0.0856-share takeover caps its upside. Antitrust review, the registration statement and the shareholder vote settle the deal, with closing targeted for…RYZRyerson HoldingLow Ryerson Holding's shares are more likely to lag the S&P 500 over three months despite an Olympic Steel merger running ahead of plan, because the 5 November 2026 fall is unexplained and fourth-quarter earnings are guided lower. The report…SEPNSepternaLow Septerna's shares are more likely to lag the S&P 500 over the next three months after a third-quarter 2026 revenue and loss miss on 9 November 2026; SEP-479 Phase 1 liver-safety data, due in the first quarter of 2027, settle the case.SGRYSurgery PartnersLow Surgery Partners' shares, at $26.58 on 12 November 2026, already price in more than HealthSpan Partners' $25.00 cash deal pays and are more likely to lag the S&P 500. Whether the rejected $28.00 bidder, reported to be UnitedHealth, returns…SLNSilence TherapeuticsLow Silence Therapeutics' shares trade just under Merck KGaA's $20-per-ADS cash takeover price, so they are more likely to lag the S&P 500 than lead it over three months. The proxy statement that dates the scheme vote, and antitrust clearance…SLSSELLAS Life Sciences GroupLow SELLAS Life Sciences is more likely to lag the S&P 500 over three months: its value rests on one Phase 3 leukemia trial, REGAL, whose topline survival result the company said on 12 November 2026 it expects this month, and the shares closed…SMCISuper Micro ComputerLow Super Micro Computer's shares are more likely to lag the S&P 500 as record sales come with a 12.7% gross margin, a 44% customer and a new China export-control report. The December-quarter result, guided at $19.5–21.5 billion, settles it.SMRNuScale PowerLow NuScale Power's shares are more likely to lag the S&P 500 because the binding ENTRA1–TVA power purchase agreement its case needs is still unsigned and undated. A signed agreement, or none by year-end 2026, settles the case.SNDKSandiskLow Sandisk's shares look more likely to lag the S&P 500 as investors price a peak in NAND flash prices after October contract prices went flat. TrendForce's November prices, Micron's December report and Sandisk's late-January results will…SNOWSnowflakeLow Snowflake's shares look more likely to lag the S&P 500, trading on AI sentiment at 19 times sales despite 37% product revenue growth; the 2 December 2026 Q3 report tests the $1,588 million guidance floor.SNXTD SYNNEXLow TD SYNNEX's Hyve server growth is consuming cash and the company just added a $1.75 billion term loan, so the shares are more likely to lag the S&P 500. The January fiscal Q4 report settles it by showing whether operating cash flow turns…SOFISoFi TechnologiesLow SoFi Technologies' shares are more likely to lag the S&P 500 after a hot October inflation report made a December Fed hike near-certain, despite a 2027 outlook above consensus. The 9 December 2026 Fed decision and the fourth-quarter report…SOUNSoundHound AILow SoundHound AI's shares are more likely to lag the S&P 500 over three months: gross margin fell and cash burn continues while breakeven is set for late 2027; the fourth-quarter report, expected around late February 2027, first tests the…SPCXSpaceXLow SpaceX shares are more likely to lag the S&P 500 because Anthropic, its largest compute customer, can leave its contracts in early 2027. The 1 December 2026 billing start of a $1.11-billion-a-month hosting deal is the first test of whether…SWIMLatham GroupLow Latham Group's fiberglass share gains lift sales 12.5%, but its shares, up 11.9% in three months, look likely to lag the S&P 500 as management plans for a flat 2027 pool market. The 2027 outlook in early March 2027 settles it.TET1 EnergyLow T1 Energy's shares are more likely to lag the S&P 500 over three months because its G2_Austin cell plant still lacks closed financing and unrestricted cash was $59.5 million at 30 September 2026; a financing close, targeted by year-end…TEMTempus AILow Tempus AI shares are more likely to lag the S&P 500 over the next three months: third-quarter revenue of $411.5 million matched forecasts and the 2026 guide rose only at its low end, after a 46.3% three-month gain. The Personalis vote on…TENTsakos Energy NavigationLow Tsakos Energy Navigation's shares look more likely to lag than lead the S&P 500 because about 80% of its fleet is on fixed charters that pass only part of record tanker rates into earnings. Its 19 November 2026 third-quarter report shows…TENBTenable HoldingsLow Tenable's revenue growth is guided to slow to about 6.9% in the fourth quarter from 9.5%, so its shares are more likely to trail the S&P 500 than lead it; the February 2027 report and first 2027 outlook show whether the Tenable One…TRUPTrupanionLow Trupanion's third-quarter beat is already in its share price, so the pet insurer's stock looks more likely to lag the S&P 500: the post-report gain faded by 10 November 2026 and new Stifel and Cantor targets sit at or below the price. The…TSLATeslaLow Tesla's shares look more likely to lag the S&P 500 over three months: operating income fell 56% while the price ran up on unsigned SpaceX merger talks. Terms, which Bloomberg says could come as soon as December, and the early-January…TWSTTwist BioscienceLow Twist Bioscience shares are more likely to lag the S&P 500 because its fiscal 2027 outlook assumes AI drug-discovery revenue grows far slower than the 175% of fiscal 2026. The fiscal first-quarter report expected in early February 2027…TXG10x GenomicsLow 10x Genomics' shares are more likely to lag the S&P 500 over the next three months: third-quarter revenue grew 1% and analysts cut targets after the report. The fourth-quarter Atera count against a plan of about 50 units settles it.ULCCFrontier Group HoldingsLow Frontier Group Holdings (Frontier Airlines) shares are more likely to lag the S&P 500: a $7.70 close on 12 November 2026 sits above most post-report targets as officers sold stock. The early-2027 fourth-quarter report settles whether…UPSTUpstart HoldingsLow Upstart Holdings is more likely to lag the S&P 500 over the next three months: it cut its 2026 outlook and October lending slowed. November originations and the fourth-quarter report will show whether the slowdown deepens or reverses.USARUSA Rare EarthLow USA Rare Earth shares look more likely to lag the S&P 500 over three months because third-quarter revenue fell to $3.0 million and the gross loss widened to $19.9 million. The company's goal of magnet sales to multiple customers by the end…VVisaLow Visa's shares are more likely to trail the S&P 500 than lead it over three months: at about 34 times trailing earnings the price reflects the franchise, while Visa's fiscal 2027 outlook slows earnings growth in a heavy contract-renewal…VALValarisLow Valaris shares are more likely to lag the S&P 500 because they trade as Transocean stock at 15.235 shares each, and Transocean's 2 November 2026 results showed lower revenue and a flat 2027 outlook. The 24 November 2026 votes, the 26…VFCV.F.Low V.F. Corporation's shares look likely to lag the S&P 500 because they already price in a Vans recovery that results have not shown. The third-quarter report, estimated for about 27 January 2027, settles whether Vans improves to a…VKTXViking TherapeuticsLow Viking Therapeutics is more likely to lag the S&P 500 over three months: $960 million in cash funds its obesity Phase 3 trials, but no pivotal efficacy result is scheduled before 2027. The ObesityWeek posters from 15 November 2026 add…VSXYVictoria's SecretLow Victoria's Secret & Co.'s shares are more likely to lag the S&P 500 after running past most analyst targets, with BofA cutting them to Neutral on 12 November 2026. The 3 December 2026 third-quarter report shows whether sales clear the top…WFCWells FargoLow Wells Fargo's shares are more likely to lag the S&P 500 than lead it because third-quarter fees fell and credit costs rose while guidance was only held. The 14 January 2027 fourth-quarter report settles it by showing whether net interest…WINGWingstopLow Wingstop's shares have run ahead of its business and are more likely to lag the S&P 500: they rose 46.8% in three months to $166.73 on 11 November 2026 despite a third cut to same-store-sales guidance. The fourth-quarter report, expected…WMTWalmartLow Walmart shares look more likely to trail the S&P 500 over the next three months because brokers already priced in its advertising- and membership-driven profit growth. The 19 November 2026 third-quarter report shows whether results can…XEX-EnergyLow X-Energy's shares are more likely to lag the S&P 500 over three months: the NRC approved Dow's Long Mott permit on 9 November 2026, but the 12 November 2026 report showed losses widening and first power stays in the early 2030s. Dow's 2027…XOMExxon MobilLow Exxon Mobil's shares are more likely to lag the S&P 500 as Brent's war premium unwinds and Goldman Sachs and Bernstein cut targets. The January 2027 fourth-quarter report settles it by showing whether refining profit held near $9.1 billion.YEXTLow Yext's margin recovery needs its AI products to restart recurring-revenue growth; the Q3 fiscal 2027 report, expected in early December 2026, must show total annual recurring revenue above the $440.8 million reported on 1 September 2026.ZMZoom CommunicationsLow Zoom Communications shares are more likely to lag the S&P 500 than lead: enterprise growth is improving but total revenue grows near 5%, and the 23 November 2026 third-quarter report must deliver a bigger raise than the market expects.
Covered
766A stock with a published research note that is not in the portfolio, not recently sold and not Watching. What this means
ATEYYAdvantestHigh AAAlcoaMedium AAONMedium ABNBAirbnbMedium ABVXAbivax SAMedium ABXAbacus Global ManagementMedium ACBAurora CannabisMedium ACCOAcco BrandsMedium ACHCAcadia HealthcareMedium ACIWACI WorldwideMedium ACLSAxcelis TechnologiesMedium ADIAnalog DevicesMedium AEISAdvanced Energy IndustriesMedium AGYSAgilysysMedium AIPArterisMedium ALABAstera LabsMedium ALKSAlkermesMedium ALNTAllientMedium AMCAmc Entertainment HoldingsMedium AMPAmeriprise FinancialMedium AMRXAmneal PharmaceuticalsMedium ANDGAndersen GroupMedium AOSLAlpha and Omega SemiconductorMedium AOUTAmerican Outdoor BrandsMedium ARCBArcBestMedium ARDTArdent HealthMedium ATENA10 NetworksMedium ATHMAutohomeMedium ATIMedium ATRCAtriCureMedium AVAHAveanna Healthcare HoldingsMedium AXTIAXTMedium BFLYButterfly NetworkMedium BHVNBiohavenMedium BILLBILL HoldingsMedium BKSYBlackSky TechnologyMedium BLLNBillionToOneMedium BLZEBackblazeMedium BMYBristol-Myers SquibbMedium BRKRBrukerMedium BTCSMedium CACICACI InternationalMedium CAKECheesecake FactoryMedium CARGCarGurusMedium CBLLCeriBellMedium CCLCarnivalMedium CDWMedium CECOCECO EnvironmentalMedium CLDTChatham Lodging TrustMedium CLOVClover Health InvestmentsMedium CLYMClimb BioMedium CMECME GroupMedium CMGChipotle Mexican GrillMedium CMPSCOMPASS PathwaysMedium CNCCenteneMedium CODICompass DiversifiedMedium COHRCoherentMedium CORTCorcept TherapeuticsMedium CRCTCricutMedium CTOSCustom Truck One SourceMedium CVLGCovenant Logistics GroupMedium DIODDiodesMedium DOCNDigitalOcean HoldingsMedium DRDDRDGOLDMedium DTDynatraceMedium DVADaVitaMedium ELVNEnliven TherapeuticsMedium ELVRElevra LithiumMedium ENTGEntegrisMedium EVGOMedium EWTXEdgewise TherapeuticsMedium EXLSExlService HoldingsMedium EXTRExtreme NetworksMedium FAFirst AdvantageMedium FBIZFirst Business Financial ServicesMedium FLEXMedium FLYWFlywire Corporation VotingMedium FNFabrinetMedium FNKOFunkoMedium FOSLFossil GroupMedium FROGJFrogMedium FWRDForward AirMedium GGenpactMedium GCMGGCM GrosvenorMedium GCTGigaCloud TechnologyMedium GENIGenius SportsMedium GEOGEO GroupMedium GFSGlobalFoundriesMedium GRNDGrindrMedium GTNGray MediaMedium HAFNHafniaMedium HNIMedium HPHelmerich & PayneMedium HRBH&R BlockMedium HURNHuron Consulting GroupMedium IAGIAMGoldMedium IMVTImmunovantMedium INNVInnovAge HoldingMedium IPARInterparfumsMedium IRWDIronwood PharmaceuticalsMedium JAKKJAKKS PacificMedium JBIOJade BiosciencesMedium JRSHJerash Holdings (US)Medium KAROKaroooooMedium KFRCKforceMedium KLACKLAMedium KMTSKestra Medical TechnologiesMedium LGNLegenceMedium LGNDLigand PharmaceuticalsMedium LILAKLiberty Latin AmericaMedium LRMRLarimar TherapeuticsMedium LTHLife Time Group HoldingsMedium LYELLyell ImmunopharmaMedium MBXMBX BiosciencesMedium MCSMarcusMedium MEDPMedpace HoldingsMedium MIRMMirum PharmaceuticalsMedium MKSIMKSMedium MNKDMannKindMedium MPWRMonolithic Power SystemsMedium MRCYMercury SystemsMedium MTRNMaterionMedium MURMurphy OilMedium MYRGMYR GroupMedium NCLHNorwegian Cruise Line HoldingsMedium NETCloudflareMedium NPNeptune Insurance HoldingsMedium NSPInsperityMedium NXTNextpowerMedium ONON SemiconductorMedium ONCBeOne MedicinesMedium ONTOOnto InnovationMedium OPIOffice Properties Income TrustMedium OSCROscar HealthMedium OUSTOusterMedium OWLBlue Owl CapitalMedium PANLPangaea Logistics SolutionsMedium PARRPar Pacific HoldingsMedium PAYCPaycom SoftwareMedium PCTYPaylocity HoldingMedium PENNPENN EntertainmentMedium PESIPerma-Fix Environmental ServicesMedium PGNYProgynyMedium PIImpinjMedium PIIPolarisMedium PKPark Hotels & ResortsMedium PKOHPark-Ohio HoldingsMedium PLSEPulse BiosciencesMedium PMTSCPI Card GroupMedium PRMPerimeter SolutionsMedium PTGXProtagonist TherapeuticsMedium PTRNPattern GroupMedium PYPLPayPal HoldingsMedium QTWOQ2 HoldingsMedium QUITAchieve Life SciencesMedium RELLRichardson ElectronicsMedium RELYRemitly GlobalMedium RHIRobert HalfMedium RIOTRiot PlatformsMedium RIVNRivian AutomotiveMedium RLAYRelay TherapeuticsMedium RRGBRed Robin Gourmet BurgersMedium RSKDRiskifiedMedium RVTYRevvityMedium RZLTRezoluteMedium SABRSabreMedium SAILSailPointMedium SANMSanminaMedium SAPMedium SEISolaris Energy InfrastructureMedium SENSSenseonics HoldingsMedium SGMTSagimet BiosciencesMedium SHIPSeanergy Maritime HoldingsMedium SILCSilicomMedium SIMOSilicon Motion TechnologyMedium SITMSiTimeMedium SMRTSmartRentMedium SONOSonosMedium SRADSportradar GroupMedium STMSTMicroelectronicsMedium STRLSterling InfrastructureMedium SXCSuncoke EnergyMedium TARSTarsus PharmaceuticalsMedium TASKTaskUsMedium TBITrueblueMedium TGTXTG TherapeuticsMedium THCTenet Healthcare Corporation NewMedium TICTIC SolutionsMedium TKTeekayMedium TLSTelosMedium TNDMTandem Diabetes CareMedium TNKTeekay TankersMedium TTMITTM TechnologiesMedium TVTXTravere TherapeuticsMedium UIUbiquitiMedium VACMarriott Vacations WorldwideMedium VGVenture GlobalMedium VIAVViavi SolutionsMedium VIRVir BiotechnologyMedium VRTVertiv HoldingsMedium VSHVishay IntertechnologyMedium VSTSVestisMedium WWayfairMedium WDAYWorkdayMedium WESTWestrock CoffeeMedium WEXMedium WPPMedium WSCWillScot HoldingsMedium WSMWilliams-SonomaMedium XMTRXometryMedium XPOMedium ZBIOZenas BioPharmaMedium ZIPZipRecruiterMedium ZYMEZymeworksMedium AAOIApplied OptoelectronicsLow ABEOAbeona TherapeuticsLow ABSIAbsciLow ABTAbbott LaboratoriesLow ACDCProFrac HoldingLow ACHRArcher AviationLow ACMRACM ResearchLow ADSKAutodeskLow ADTNADTRAN HoldingsLow AEHRAehr Test SystemsLow AEMAgnico Eagle MinesLow AEOAmerican Eagle OutfittersLow AESIAtlas Energy SolutionsLow AEYEAudioEyeLow AGCOLow AGENAgenusLow AGIOAgios PharmaceuticalsLow AGLTChurchill Capital Corp XILow AGMFederal Agricultural MortgageLow AGXArganLow AIFFFirefly NeuroscienceLow AIROAIRO Group HoldingsLow AKAMAkamai TechnologiesLow AKBAAkebia TherapeuticsLow AKTSAktis OncologyLow ALGMAllegro MicroSystemsLow ALHCAlignment HealthcareLow ALKAlaska Air GroupLow ALMSAlumisLow ALTOAlto IngredientsLow ALVOAlvotechLow AMBAAmbarellaLow AMKRAmkor TechnologyLow AMLXAmylyx PharmaceuticalsLow AMRAlpha Metallurgical ResourcesLow AMSCAmerican SuperconductorLow ANABAnaptysBioLow ANFAbercrombie & FitchLow ANROAlto NeuroscienceLow APHAmphenolLow APLDApplied DigitalLow APPSDigital TurbineLow AQSTAquestive TherapeuticsLow ARCTArcturus Therapeutics HoldingsLow ARECAmerican ResourcesLow ARESAres ManagementLow ARISAris MiningLow ARQQArqit QuantumLow ARTVArtiva BiotherapeuticsLow ARXAccelerant HoldingsLow ASANAsanaLow ASMBAssembly BiosciencesLow ASOAcademy Sports and OutdoorsLow ASPNAspen AerogelsLow ASSTStriveLow ASTHAstrana HealthLow ASXASE Technology HoldingLow ASYSAmtech SystemsLow ATEXAnterixLow AUAngloGold AshantiLow AUGOAura MineralsLow AURAurora InnovationLow AUTLAutolus TherapeuticsLow AVLNAvalyn PharmaLow AVRAnteris Technologies GlobalLow AVTXAvalo TherapeuticsLow AVXLAnavex Life SciencesLow AYAAya Gold & SilverLow AZZLow BAKBraskemLow BANDBandwidthLow BAXBaxter InternationalLow BBBlackBerryLow BBARBanco BBVA ArgentinaLow BBNXBeta BionicsLow BBYBest BuyLow BCAXBicara TherapeuticsLow BHBiglari HoldingsLow BHEBenchmark ElectronicsLow BIOABioAge LabsLow BIRDSmartbirdLow BIRKBirkenstock HoldingLow BKNGBooking HoldingsLow BLDPBallard Power SystemsLow BLKBBlackbaudLow BLMNBloomin' BrandsLow BLSHBullishLow BMABanco MacroLow BMEABiomea FusionLow BMNRBitMine Immersion TechnologiesLow BOLDBoundless BioLow BOOMDMC GlobalLow BOXLow BRBRBellRing BrandsLow BRCBBlack Rock Coffee BarLow BROSDutch BrosLow BSINBig Sky IndustrialLow BSPBending Spoons S.p.A.Low BTBTBit DigitalLow BTDRBitdeer Technologies GroupLow BTEBaytex EnergyLow BTGOBitGo HoldingsLow BTUPeabody EnergyLow BULLWebullLow BVSBioventusLow BWINBaldwin Insurance GroupLow CABACabaletta BioLow CADLCandel TherapeuticsLow CAICaris Life SciencesLow CALCaleresLow CBRLCracker Barrel Old Country StoreLow CCCCCC Intelligent Solutions HoldingsLow CCSCentury CommunitiesLow CERSCerusLow CEVALow CGCCanopy GrowthLow CGEMCullinan TherapeuticsLow CIENCienaLow CLDXCelldex TherapeuticsLow CLFCleveland-CliffsLow CLFDClearfieldLow CLMTCalumetLow CLPTClearPoint NeuroLow CLSCelesticaLow CLSKCleanSparkLow CLWClearwater PaperLow CMBTCMB.TECH NVLow CMRCCommerce.com, Inc. Series 1Low CNHCNH IndustrialLow CNMDCONMEDLow COHULow COMPCompassLow COOKTraegerLow CPIXCumberland PharmaceuticalsLow CRCLCircle Internet GroupLow CRDLCardiol TherapeuticsLow CRDOCredo Technology Group HoldingLow CRSCarpenter TechnologyLow CRTOCriteoLow CRVSCorvus PharmaceuticalsLow CSIQCanadian SolarLow CTKBCytek BiosciencesLow CTSHCognizant Technology SolutionsLow CVICVR EnergyLow CXTCrane NXTLow CXWCoreCivicLow DAVELow DDD3D SystemsLow DDOGDatadogLow DFINDonnelley Financial SolutionsLow DFTXDefinium TherapeuticsLow DGIIDigi InternationalLow DGXXDigi Power XLow DHTDHT HoldingsLow DINOHF SinclairLow DJTTrump Media & Technology GroupLow DKDelek US HoldingsLow DLTRDollar TreeLow DNAGinkgo Bioworks HoldingsLow DNTHDianthus TherapeuticsLow DOCSDoximityLow DOCUDocuSignLow DPRODraganflyLow DSGNDesign TherapeuticsLow DSGRDistribution Solutions GroupLow DSXDiana ShippingLow DTILPrecision BioSciencesLow DUOTDuos Technologies GroupLow DYNDyne TherapeuticsLow EDITEditas MedicineLow EDRYEuroDryLow EFOREverforthLow EFXEquifaxLow EFXTEnerflexLow EGOEldorado GoldLow ELEElemental RoyaltyLow ENPHEnphase EnergyLow ENVAEnova InternationalLow EOLSEvolusLow EPCEdgewell Personal CareLow EPRXEupraxia PharmaceuticalsLow EQNREquinor ASALow ERASErascaLow ESTCElasticLow EXFYExpensifyLow EXKEndeavour SilverLow FACFactorial EnergyLow FBINFortune Brands InnovationsLow FCELFuelCell EnergyLow FDMT4D Molecular TherapeuticsLow FETForum Energy TechnologiesLow FIGFigmaLow FIVNFive9Low FLXSFlexsteel IndustriesLow FORMFormFactorLow FOURShift4 PaymentsLow FRDFriedman IndustriesLow FRNMFreenomeLow FROFrontlineLow FSLRFirst SolarLow FSLYFastlyLow FSMFortuna MiningLow FTKFlotek IndustriesLow FTNTFortinetLow FWDIForward IndustriesLow GCOGenescoLow GCTSGCT Semiconductor HoldingLow GDRXGoodRx HoldingsLow GERNGeronLow GGALGrupo Financiero GaliciaLow GHGuardant HealthLow GHRSGH ResearchLow GLUEMonte Rosa TherapeuticsLow GLWCorningLow GLXYGalaxy DigitalLow GOGOLow GOLFAcushnet HoldingsLow GPRKGeoparkLow GRPNGrouponLow GSHDGoosehead InsuranceLow GTMZoomInfo TechnologiesLow GWREGuidewire SoftwareLow HBBHamilton Beach Brands HoldingLow HCCWarrior Met CoalLow HELPCybinLow HGTYHagertyLow HIMXHimax TechnologiesLow HIVEHIVE Digital TechnologiesLow HLHecla MiningLow HMYHarmony Gold MiningLow HOVHovnanian EnterprisesLow HPEHewlett Packard EnterpriseLow HPKHighPeak EnergyLow HPPHudson Pacific PropertiesLow HROWHarrowLow HTLDHeartland ExpressLow HTZHertz Global HoldingsLow HUTHut 8Low HVTHaverty Furniture CompaniesLow HZOMarineMaxLow IARTIntegra LifeSciences HoldingsLow IBKRInteractive Brokers GroupLow ICHRIchor HoldingsLow IDYAIDEAYA BiosciencesLow IESCIES HoldingsLow IHRTiHeartMediaLow IKTInhibikase TherapeuticsLow ILMNIlluminaLow IMMXImmix BiopharmaLow IMOSChipMOS TECHNOLOGIESLow IMRNImmuronLow IMRXImmuneeringLow INBXInhibrx BiosciencesLow INDIindie SemiconductorLow INFQInfleqtionLow INGNInogenLow INHDInno HoldingsLow INODInnodataLow INSPInspire Medical SystemsLow INSWInternational SeawaysLow INTAIntappLow INTRInterLow IOVAIovance BiotherapeuticsLow IPXIperionXLow IQiQIYILow IRDMIridium CommunicationsLow ITGartnerLow ITGRInteger HoldingsLow ITUBItau Unibanco HoldingLow IVAInventivaLow JBHTJ.B. Hunt Transport ServicesLow JBLUJetBlue AirwaysLow JILLJ.JillLow JOBYJoby AviationLow JWELJowell GlobalLow KCKingsoft Cloud HoldingsLow KEELKeel InfrastructureLow KELYAKelly ServicesLow KEYSKeysight TechnologiesLow KGSKodiak Gas ServicesLow KLCKinderCare Learning CompaniesLow KMXCarMaxLow KODKEastman KodakLow KOSKosmos EnergyLow KROKronos WorldwideLow KRTKarat PackagingLow KURAKura OncologyLow KYMRKymera TherapeuticsLow LARLithium ArgentinaLow LEGNLegend BiotechLow LFSTLifeStance Health GroupLow LGIHLGI HomesLow LILALiberty Latin AmericaLow LNCLincoln NationalLow LOVELovesacLow LPGDorian LpgLow LSTRLandstar SystemLow LTRXLantronixLow LUXELuxExperience B.V.Low LZLegalZoom.comLow MMacy'sLow MAMAMama's CreationsLow MANManpowerGroupLow MARAMARA HoldingsLow MASS908 DevicesLow MATMattelLow MATVMativ HoldingsLow MAZEMaze TherapeuticsLow MCHPMicrochip TechnologyLow MDBMongoDBLow MEIMethode ElectronicsLow MESOMesoblastLow MGMMGM Resorts InternationalLow MGNXMacroGenicsLow MGTXMeiraGTx HoldingsLow MKTXMarketAxess HoldingsLow MLKNMillerKnollLow MMEDMiniMed GroupLow MMYTMakeMyTripLow MNPRMonopar TherapeuticsLow MNTNLow MOVMovado GroupLow MPCMarathon PetroleumLow MQMarqetaLow MRAMEverspin TechnologiesLow MRXMarex GroupLow MTHMeritage HomesLow MTSIMACOM Technology Solutions HoldingsLow MXMagnachip SemiconductorLow MXLMaxLinearLow MYEMyers IndustriesLow NABLN-ableLow NATNordic American TankerLow NAVNNavanLow NBTXNanobiotixLow NEOGNeogenLow NESRNational Energy Services ReunitedLow NEXANexa ResourcesLow NGNENeurogeneLow NIQNIQ Global IntelligenceLow NKTRNektar TherapeuticsLow NNENano Nuclear EnergyLow NOGNorthern Oil and GasLow NOKNokiaLow NRIXNurix TherapeuticsLow NTAPNetAppLow NUTXNutex HealthLow NVAXNovavaxLow NVCRNovoCureLow NVCTNuvectis PharmaLow NVECNVELow NWLNewell BrandsLow NWPXNWPX InfrastructureLow NXHBed Bath & BeyondLow NXPINXP SemiconductorsLow OBIOOrchestra BioMed HoldingsLow OCCOptical CableLow ODFLOld Dominion Freight LineLow OGNOrganonLow OIIOceaneering InternationalLow OKTALow OMDAOmada HealthLow OMEROmerosLow OOMALow OPENOpendoor TechnologiesLow ORBSEightco HoldingsLow ORICOric PharmaceuticalsLow OTEXOpen TextLow OTLYOatly Group ABLow OXMOxford IndustriesLow PEverpureLow PACBPacific Biosciences of CaliforniaLow PAGSPagSeguro DigitalLow PATHUiPathLow PAYPaymentus HoldingsLow PAYOPayoneer GlobalLow PAYSPaysignLow PBFPBF EnergyLow PBIPitney BowesLow PBRPetroleo Brasileiro S.A.-PetrobrasLow PCTPureCycle TechnologiesLow PDFSPDF SolutionsLow PDSPrecision DrillingLow PENGPenguin SolutionsLow PGENPrecigenLow PLPlanet Labs PBCLow PLAYDave & Buster's EntertainmentLow PLPCPreformed Line ProductsLow PLTKPlaytika HoldingLow PNRGPrimeEnergy ResourcesLow POWLPowell IndustriesLow PPTAPerpetua ResourcesLow PRGOPerrigoLow PRGSProgress SoftwareLow PRLBProto LabsLow PRPOPrecipioLow PRTHPriority Technology HoldingsLow PSXPhillips 66Low PTENPatterson-UTI EnergyLow PURRHyperliquid StrategiesLow PVHLow QLYSQualysLow QSIQuantum-SiLow QTRXQuanterixLow QUBTQuantum ComputingLow QUIKQuickLogicLow QUREuniQureLow RAPPRapport TherapeuticsLow RBLXRobloxLow RBRKRubrikLow RCKTRocket PharmaceuticalsLow RCKYRocky BrandsLow RCMTRCM TechnologiesLow RDACRising Dragon AcquisitionLow RDWRedwireLow RFAIRF Acquisition Corp IILow RLYBRallybioLow RMBSRambusLow ROGRogersLow RPAYRepay HoldingsLow RUMRumbleLow RVMDRevolution MedicinesLow RXRXRecursion PharmaceuticalsLow RXTRackspace TechnologyLow SSentinelOneLow SAFTSafety Insurance GroupLow SAHSonic AutomotiveLow SANASana BiotechnologyLow SATLSatellogicLow SBETSharpLinkLow SBSLow SCZMSantacruz Silver MiningLow SESeaLow SEERLow SFIXStitch FixLow SHAKShake ShackLow SHLSShoals Technologies GroupLow SHOOSteven MaddenLow SIDUSidus SpaceLow SITCSITE CentersLow SKMSK TelecomLow SKWDSkyward Specialty Insurance GroupLow SKYASkyAILow SLDBSolid BiosciencesLow SMSM EnergyLow SMTCSemtechLow SMTISanara MedTechLow SMWBSimilarwebLow SNAPLow SNDRSchneider NationalLow SNDXSyndax PharmaceuticalsLow SNEXStoneX GroupLow SNPSSynopsysLow SOPHSOPHiA GENETICS SALow SPIRSpire GlobalLow SPRYARS PharmaceuticalsLow SPSCSPS CommerceLow SPTSprout SocialLow SPXCSPX TechnologiesLow SRPTSarepta TherapeuticsLow SRZNSurrozenLow SSLSasolLow SSRMSSR MiningLow SSTISoundThinkingLow STAASTAAR SurgicalLow STLNStarling OncologyLow STNEStoneCoLow STROSutro BiopharmaLow STTKShattuck LabsLow STUBStubHub HoldingsLow STXSeagate Technology HoldingsLow SVVSavers Value VillageLow SWKSSkyworks SolutionsLow SYNASynapticsLow SYRESpyre TherapeuticsLow TALTAL Education GroupLow TBLATaboola.comLow TDUPThredUpLow TEAMAtlassianLow TECHBio-TechneLow TENXTenax TherapeuticsLow TERTeradyneLow THTarget HospitalityLow TITNTitan MachineryLow TKNOAlpha TeknovaLow TLRYTilray BrandsLow TLYSTilly'sLow TMCTMC the metalsLow TNETTrinet GroupLow TNGXTango TherapeuticsLow TRIPTripAdvisorLow TRMDTORMLow TSATTelesatLow TSEMTower SemiconductorLow TSHATaysha Gene TherapiesLow TSSITSSLow TTANServiceTitanLow TWLOTwilioLow UCTTUltra Clean HoldingsLow UGPUltrapar ParticipacoesLow ULBIUltralifeLow UMCUnited MicroelectronicLow UNITUniti GroupLow URGNUroGen PharmaLow UROYUranium RoyaltyLow UTZUtz BrandsLow UUUUEnergy FuelsLow VCYTVeracyteLow VECOVeeco InstrumentsLow VERIVeritoneLow VERULow VETVermilion EnergyLow VICRVicorLow VIOTViomi TechnologyLow VLOValero EnergyLow VMIValmont IndustriesLow VORVor BiopharmaLow VOYGVoyager TechnologiesLow VRAVera BradleyLow VREXVarex ImagingLow VRNSVaronis SystemsLow VSTMVerastemLow WDCWestern DigitalLow WEYSWeyco GroupLow WITWiproLow WIXWix.comLow WKWorkivaLow WLFCWillis Lease FinanceLow WNCWabash NationalLow WOLFWolfspeedLow WRLDWorld AcceptanceLow WTWisdomTreeLow WTIW&T OffshoreLow WTTRSelect Water SolutionsLow WULFTeraWulfLow WYHGLow XENEXenon PharmaceuticalsLow XGNExagenLow XHGXChange TEC.INCLow XOSLow XPLow XPOFXponential FitnessLow XRAYDentsply SironaLow XRPNArmada Acquisition Corp. IILow XTLBXTL BiopharmaceuticalsLow XXITwenty One CapitalLow YAASYouxin TechnologyLow YSSYork Space SystemsLow ZBRAZebra TechnologiesLow ZENAZenaTechLow ZSZscalerLow ZURAZura BioLow
Archetype mix
- Theme leader 93 · 8%
- Picks and shovels 136 · 12%
- Second-order beneficiary 66 · 6%
- Business pivot 361 · 32%
- Event-driven 238 · 21%
- Crowd-driven 36 · 3%
- Distinct case 195 · 17%
Freshness · last analysed
- ≤ 7 days 1,124 · 100%
- ≤ 30 days 1 · <1%
Common questions
What is a FrontierPicks research note?
One page of research on one stock, written by Claude: the current thesis, the archetype the stock is trading as, the next dated catalyst, and a kill line, the note's own test, stated in advance, of what would prove it wrong: a price level, a business fact, or both. Every note is dated and rewritten as the facts change.
How many stocks does FrontierPicks cover?
1,125 US stocks have a research note right now. The research notes on all 1,125 stocks include both a dated thesis and a kill line, the stated test that would prove the note wrong. Coverage follows the research: the stocks in the portfolio, the themes on the move, and the largest and most-searched US companies. A stock's page stays up after the research moves on, dated and re-read on the rolling cycle. 17 stocks are read first: the portfolio's holdings and recent sales, and stocks in an accelerating theme. Each is re-read at least every four days. Every covered stock is checked every morning from Monday to Saturday for what changed. The other 1,108 are re-read within 5 sessions. A stock with new results, a filing or another dated event is re-read within 4 days of it.
Is AI-generated stock research reliable?
It should be judged the way any research is judged: on its reasoning and on results. FrontierPicks is built to make both checkable. Every note names what would prove it wrong before the outcome is known and lists its dated sources, and a portfolio built on the research is measured against the S&P 500 in public from 10 November 2026, every buy and sale with the dated fact behind it. It is research to evaluate, not advice.
How often are the research notes updated?
On a rolling cycle, not uniformly. 17 stocks are read first: the portfolio's holdings and recent sales, and stocks in an accelerating theme. Each is re-read at least every four days. Every covered stock is checked every morning from Monday to Saturday for what changed. The other 1,108 are re-read within 5 sessions. A stock with new results, a filing or another dated event is re-read within 4 days of it. Claude re-reads a covered stock against fresh price, filing and news data and rewrites the note when the facts move; each page shows its own last-updated date rather than a sitewide timestamp, so the cadence is checkable stock by stock.
Why is there no research note on Anthropic?
Claude, the AI model that writes every research note here and decides the portfolio, is made by Anthropic. A model cannot be a neutral judge of the company that made it, so Claude does not research Anthropic and the portfolio never buys its shares.
Why Claude does not research Anthropic →